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Polymeric microspheres have been widely investigated as delivery systems and are 
clinically used today.  We examined the use of poly(lactide-co-glycolide) (PLGA) microspheres 
in delivery systems for soft tissue engineering, chemotherapeutic delivery, and cartilage tissue 
engineering.  Soft tissue defects due to trauma or tumor removal remain a clinical challenge.  We 
examined the use of PLGA microspheres and adipose derived stem cells (ASCs) to fill in soft 
tissue defects.   We first demonstrated the use of PLGA microspheres to increase ASC 
proliferation and survival by encapsulating fibroblast growth factor-2 (FGF-2).  The released 
FGF-2 increased ASC proliferation and survival in vitro.  Addition of the FGF-2 microspheres in 
an in vivo study resulted in an increase in angiogenesis.  We then examined the ability of 
released adipogenic factors to induce the differentiation of ASCs into mature adipocytes.  Oil red 
O staining and Western blots confirmed that adipogenesis was induced by the released factors.  
The second goal was to examine a delivery system to reduce the risk of local recurrence in breast 
cancer patients following a lumpectomy.  Breast cancer lumps are commonly treated by tumor 
removal (lumpectomy) followed by radiation or chemotherapy, and both have adverse side 
effects. PLGA microspheres encapsulating doxorubicin were embedded with a natural scaffold, 
gelatin, to locally deliver chemotherapy and maintain the breast contour.  Our results 
demonstrated a more controlled release from microspheres embedded within gelatin compared to 
microspheres alone.  Released doxorubicin killed tumor cells in vitro.  The implantation of the 
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scaffolds in vivo resulted in tumor ablation.  Local and systemic toxicity were not observed even 
though a dose 60 times the normal dose was given.  Our next objective was to analyze the release 
of TGF-beta1 (TGF-β1) from PLGA microspheres incorporated into a synthetic hydrogel, 
poly(ethylene glycol) (PEG)-genipin for cartilage repair.  The release of TGF- β1 was dependent 
upon the genipin concentration of the hydrogel.  The released TGF- β1 was bioactive, as 
demonstrated by the inhibition of mink lung cell proliferation.  The final goal was to develop and 
characterize a hydrogel based on PEG-genipin to gel in situ.  As such, we examined genipin and 
multi-branched aminated PEG.  Gelation time was affected by pretreating genipin.  Exposure of 
the genipin aqueous solution to air and oxygen decreased the gelation time.  PEG structure also 
had an effect on gelation time.  The gelation time was reduced by utilizing 4-arm PEG and 
increasing the temperature from 25oC to 37oC.  The results of this thesis demonstrate the efficacy 
of PLGA microspheres embedded in hydrogels for use as delivery systems for soft tissue and 
cartilage tissue engineering.  The delivery systems can be modified to tailor delivery rates, 
deliver multiple drugs/growth factors, tailor degradation, and promote tissue growth.   
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1.0  INTRODUCTION 
Delivery systems have been utilized for localization, prolonged release, and protection of 
drugs.  The main reason to use delivery systems is to obtain and maintain a desired range of drug 
levels in the system.  An ideal system is controlled release in which the levels are maintained 
within the desired range over long periods of time.  The most basic form of a delivery system is 
an intravenous (IV) pump.  However, due to the advances in materials science and in the area of 
biomaterials, controlled release can be maintained by polymer formulations.  Controlled release 
can lead to improved drug performance, decreased side effects, ease of use, and lower costs than 
developing new drugs.  Some of the critical factors in the design are the properties of the drug, 
the administration route, and the target tissue.  Delivery systems can be diffusion, chemically, 
solvent, or external activation controlled.  Bioerodible systems would not have to removed and 
are thus advantageous.  We have designed biodegradable delivery systems utilizing polymer 
microspheres and hydrogel scaffolds for soft tissue and cartilage tissue engineering applications.  
1.1 DELIVERY SYSTEMS AND TISSUE ENGINEERING 
The advantages of delivery systems have led to their use clinically.  Polymer delivery 
systems have been utilized for delivery of steroids, Norplant® (Wyeth Pharmaceuticals) and 
Progestasert®; human growth hormone, Nutropin Depot® (Genentech-Alkermes); and glaucoma 
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therapy, Ocusert®. Delivery systems are optimal due to the reduction of adverse reactions and 
side effects.  Such is the case for chemotherapeutic drugs, which have numerous side effects.   
1.1.1 Tissue engineering 
Tissue engineering is a rapidly growing field.  One approach to tissue engineering is 
combining the fields of cell therapy and biomaterials.  The approach utilizes cells, scaffolds, and 
growth factors.  Cell therapy has recently become a reality.  Autologous cell sources can be 
utilized to create biological substitutes for injured or damaged tissues.  However, a support 
system and favorable microenvironment must be supplied for cells to proliferate, differentiate, 
and produce the necessary factors to heal the surrounding area.  In the natural environment, these 
are provided by the extracellular matrix (ECM).  In tissue engineering, these criteria can be met 
by the combination of scaffold and growth factor delivery.  The scaffold must support the cells, 
allow them to proliferate, and maintain their phenotype, or in some cases help induce their 
differentiation.  It is also important that the scaffold can be degraded so that the ECM produced 
by the cells can be deposited and eventually replace the scaffold.  ECM also contains growth 
factors that can be released.  Injection of growth factors is insufficient since they diffuse away 
from the area and have short half lives.  By incorporating growth factors into the scaffold, or 
separately, prolonged delivery can be obtained.  In some cases, providing the scaffold and 
growth factor delivery is enough to regenerate or repair tissue without cells.   
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1.2 BIOMATERIALS 
1.2.1 Polyesters 
Poly(lactide-co-glycolide) (PLGA), a polyester, is an FDA approved polymer.   PLGA 
was first developed for use in absorbable sutures.  PLGA has since been utilized for delivery 
devices and tissue engineering.  PLGA (Figure 1-1) is a copolymer of poly(lactide) (Figure 1-2) 
and poly(glycolide) (Figure 1-3).  Poly(L-lactide) (PLLA) is a crystalline polymer, poly(D,L-
lactide) (PDLA) is an amorphous polymer, and poly(glycolide) (PGA) is a crystalline polymer.  
Polyesters are degraded by hydrolytic cleavage of ester linkages, resulting in bulk erosion.  
Homogenous degradation occurs throughout the polymer scaffold and the rate of water 
penetration is greater than the conversion of water soluble fragments.  The molecular weight 
decreases due to continuous cleavage.  The polymer scaffold will retain its shape and mass until 
significant degradation occurs.  The PLGA chains are cleaved to monomeric acids that are then 
eliminated by the Kreb’s cycle as CO2 and in the urine as water.[5]  PLGA polymers can be 
prepared in different ratios to tailor the in vivo degradation rates (Table 1-I). 
 
Figure 1-1.  Structure of PLGA. 
 
Figure 1-2.  Structure of PLA. 
 
Figure 1-3. Structure of PGA. 
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Table 1-I.  Degradation times of polyesters. [6] 
Polymer Approximate biodegradation 
time (months) 
PLLA 18-24 
PDLA 12-16 
PGA 2-4 
50:50 PLGA 2 
85:15 PLGA 5 
1.2.2 Hydrogels  
Hydrogels are crosslinked networks that provide a three-dimensional environment to 
mimic the natural environment of tissues.  The equilibrium swelling allows the diffusion of 
nutrients into the hydrogel and waste out.  Hydrogels, which are typically water-insoluble 
swollen networks of water-soluble polymer chains, are useful for numerous tissue engineering 
applications[7-11].   
Poly(ethylene glycol) (PEG) is a non-toxic, non-immunogenic polymer. PEG is one of 
the most widely studied polymers.[12-17]  PEG hydrogels have been investigated as delivery 
systems. PEG-dimethacrylate (PEGDM) photo-crosslinkable hydrogels have been examined for 
the delivery of insulin like growth factor–I (IGF-I) and TGF-β1.[18] PEG-grafted chitosan and 
crosslinked PEG-polyacrylamide have been utilized as delivery systems.[19] Mikos’ lab has 
examined degradable oligo(poly(ethylene glycol)fumarate) hydrogels (OPF).  The OPF 
hydrogels have been studied for delivery of TGF-β1[20, 21] and dual delivery of IGF-I and TGF-
β1 from gelatin microspheres within the OPF gels.[22]  
PEG hydrogels have been examined as cell scaffolds.  Fibroblasts and chondrocytes 
adhere and proliferate on PEG hydrogels crosslinked by hydrolyzable polyrotaxane.[23, 24]  
Smooth muscle cells adhere to PEG crosslinked with genipin.[25] PEG-poly(caprolactone) 
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(PCL) scaffolds and PCL scaffolds were evaluated for human and rat bone marrow derived 
stromal cells.  Cells adhered better to PEG-PCL copolymers than the PCL homopolymer.[26] 
Furthermore, PEG hydrogels can be utilized as cell carriers.  Quickly gelling hydrogels 
can encapsulate cells within their three-dimensional environment.   PEGDM hydrogels have 
been utilized to encapsulate chondrocytes.[18, 27]  PEG-LA-DM was reacted with poly(vinyl 
alcohol) (PVA) forming photo-crosslinkable hydrogels to encapsulate chondrocytes.[28]  
1.3 MICROSPHERES AS DELIVERY SYSTEMS 
1.3.1 Microsphere preparation 
Microspheres can be prepared by different techniques, spray drying, single emulsion, 
double emulsion, and phase separation. The technique of encapsulation should meet the 
requirements set by the optimal protein/drug loading, stability of encapsulated protein/drug, low 
burst effects, high yield of particles, and manipulation of release properties. 
Microspheres can be prepared utilizing a single, oil-in-water (o/w), emulsion/solvent 
extraction technique.  The polymer is dissolved with the dissolved or suspended drug in an 
organic solvent (oil).  This oil phase is then added to an aqueous solution (water).  The organic 
solvent is removed by evaporation, resulting in an aqueous solution with hardened microspheres.  
This technique is best for more hydrophobic drugs.  A water-soluble drug encapsulated using the 
single emulsion technique will probably result in a low encapsulation efficiency since the drug 
will most likely diffuse into the external aqueous phase. 
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The double emulsion, water in oil in water (w/o/w), solvent extraction technique is more 
favorable for water soluble drugs.  The drug is first dissolved in an aqueous solution (water), 
which is emulsified with the polymer dissolved in an organic solvent (oil).  This first emulsion is 
then added to a large aqueous solution (water), resulting in a second emulsion (w/o/w).  As the 
solution is stirred, the solvent evaporates, and the polymer hardens forming microspheres (Figure 
1-4).   
 
Figure 1-4.  Preparation of polymer microspheres utilizing single or double emulsion technique. 
1.3.2 Preparation parameters 
The parameters used to prepare the microspheres can affect the microsphere size, 
encapsulation efficiency, and burst effect.  The size of the microspheres is affected by polymer 
concentration, stirring rate, and emulsion time.  The diameter of the microspheres increases 
linearly with increasing polymer concentration and decreases with an increase in vortexing 
time.[29]  The number and size of pores is affected by the volume of internal aqueous phase in a 
double emulsion preparation.[29]   
The encapsulation efficiency has been shown to be affected by polymer concentration, 
method of preparation, internal aqueous volume, stirring time for solvent evaporation, and 
stabilization of the primary emulsion.  Increasing the polymer concentration, increases the 
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encapsulation efficiency.[29, 30]  This is because the time for the microspheres to solidify is 
shorter, thus less time for the drug to transport into the external aqueous solution.  The viscosity 
of the polymer drug dispersion in increased and thus it is more difficult for the drug to diffuse 
through the polymer solution to the external aqueous solution.  An increase in internal aqueous 
volume decreases encapsulation efficiency.[31]  An increase in internal aqueous phase may lead 
to aqueous drops present at the surface of emulsion and thus facilitate drug loss to the external 
water phase.  The stirring time that allows solvent evaporation affects the encapsulation 
efficiency.  Increasing the stirring time leads to a decrease in encapsulation efficiency due to 
drug loss to the external aqueous phase.[31] However, this can be overcome by the addition of 
salts to the external aqueous phase.  When the primary emulsion is stable, a higher encapsulation 
efficiency follows.  The primary emulsion can be stabilized by the addition of emulsifying agents 
such as bovine serum albumin (BSA), PVA, or Tween-80.  
The release and burst effect of microspheres can also be affected by the preparation 
parameters.  Smaller microspheres have a larger burst effect and a quicker release.  The release 
rate increases with an increasing internal aqueous volume.[29]  An increasing internal aqueous 
volume also results in more pores, which will lead to a quicker release. Low molecular weight 
polymers result in a high burst release, because the polymer is more soluble in the organic 
solvent and thus undergoes a slower solidification.[32]  A lower molecular weight also results in 
more porous microspheres and smaller microspheres, both lead to a quicker release.  The 
stabilizers affect the release kinetics as well as the encapsulation efficiency.  By increasing the 
PVA concentration, the diameter is decreased; however, the initial burst is decreased.[32]  The 
PVA may reduce the migration of the drug into the external aqueous phase.   
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1.3.3 Microspheres in scaffolds 
Microspheres can be utilized as a delivery system alone.  Studies have demonstrated that 
microspheres typically stay at the site of injection in vivo and are unlikely to cross biological 
barriers.[33]    Phagocytosis of microparticles typically occurs in particles less than 10µm in 
diameter.[33]  However, the desire to incorporate microspheres within scaffolds for tissue 
engineering or a more controlled release has been examined.  Zhang et al. examined the 
incorporation of hydroxyl-functionalized glycerol poly(ε-caprolactone) (PGCL) microspheres in 
poly(N-isopropylacrylamide) (PNIPAAm) hydrogels.[34]  Leach et al. examined the release of 
BSA from glycidyl methacrylate-hyaluronic acid (GMHA)-PEG hydrogels and BSA in PLGA 
microspheres in the GMHA-PEG hydrogels.  The microspheres in the hydrogel extended the 
release of BSA compared to BSA in hydrogels alone.[35]  Holland et al. has examined the 
release of growth factors from gelatin microspheres embedded within OPF hydrogels.  The 
release of TGF-β1 from gelatin microspheres in OPF could be tailored by altering the OPF 
formulation and crosslinking time.[20, 21]  Holland et al. further examined the delivery of both 
IGF-I and TGF-β1 from gelatin microspheres in OPF hydrogels.[22]   
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1.4 PROJECT OBJECTIVES 
1.4.1 Objective #1: Delivery of FGF-2, insulin, and dexamethasone to induce adipogenesis 
of adipose derived stem cells for soft tissue engineering. 
Objective #1:  Develop an injectable system for soft tissue reconstruction utilizing 
PLGA microspheres to promote adipose derived adult stem cells (ASCs) differentiation and 
survival.  We will examine the effects of released FGF-2, insulin, and dexamethasone on ASCs.   
Hypothesis: The released FGF-2 will promote ASC proliferation in vitro and 
angiogenesis in vivo.  The released dexamethasone and insulin will promote the differentiation of 
the ASCs in vitro. 
1.4.2 Objective #2: Controlled release of chemotherapy from PLGA microspheres/gelatin 
scaffolds as adjuvant therapy for breast cancer. 
Objective #2: Develop a material that can be placed in the breast following a 
lumpectomy that will maintain controlled delivery of a chemotherapeutic agent locally to 
decrease the risk of local recurrence.  The material will also temporarily maintain the volume and 
contour of the breast and promote tissue ingrowth and remodeling. We will encapsulate 
doxorubicin in PLGA microspheres and embed these in gelatin scaffolds.  The effectiveness of 
the scaffolds to eradicate tumors will be assessed in vitro and in vivo.  
Hypothesis:  By embedding the microspheres in gelatin, the release of doxorubicin will 
be further controlled.  The released doxorubicin will result in cell death in vitro and tumor 
eradication in vivo. 
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1.4.3 Objective #3: The controlled release of TGF-β1 from PEG-genipin biodegradable 
hydrogels for cartilage repair. 
Objective #3: Develop a system to locally deliver TGF-β1 for cartilage regeneration.  
We will assess the release of TGF-β1 from PLGA microspheres and PLGA microspheres 
embedded within PEG-genipin hydrogels in vitro.   
Hypothesis: The release of proteins from the PLGA microspheres within PEG-genipin 
hydrogels will differ depending on the degree of crosslinking. The dissolution rate in vivo can be 
tailored depending on the degree of crosslinking. 
1.4.4 Objective #4: Modifications of PEG-genipin to increase gelation rate 
Objective #4: Design and develop an injectable PEG-based biodegradable hydrogel.  
We will examine bi-functional, four-arm, and eight-arm amino-terminated PEG.  We will 
characterize each of the hydrogels.   
Hypothesis: By increasing the number of amine groups, the gelation time will decrease, 
thus the 8-arm PEG will gel faster than a 4-arm or diamine PEG.  The gelation of PEG-genipin 
can be enhanced by varying parameters such as, temperature, exposure to air, and exposure to 
oxygen.  The degradation of the 8-arm and 4-arm PEG hydrogels will be slower than the diamine 
PEG hydrogels. 
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2.0  DELIVERY OF FGF-2, INSULIN, AND DEXAMETHASONE TO INDUCE 
ADIPOGENESIS OF ADIPOSE DERIVED STEM CELLS FOR SOFT TISSUE 
ENGINEERING 
2.1 INTRODUCTION 
Soft tissue defects due to trauma or tumor resection often require reconstructive surgery.  
Autologous stem cell therapy has become a possibility for tissue reconstruction.  In this study, 
we examined the use of adipose derived adult stem cells (ASCs) for soft tissue reconstruction.  
We designed an injectable system to deliver cells and growth factors.  Fibroblast growth factor-2 
(FGF-2) was encapsulated in PLGA microspheres.  Released FGF-2 increased ASC proliferation 
and survival in vitro.  ASCs were seeded on injectable small intestinal submucosa particles and 
injected subcutis along with FGF-2 microspheres in nude mice. FGF-2 microspheres increased 
angiogenesis in vivo; however, adipogenesis of the ASCs was not observed.  Adipogenic factors, 
insulin and dexamethasone, were encapsulated in PLGA microspheres.  The released factors 
induced adipogenesis of the ASCs in vitro.  We have developed an injectable system to create a 
suitable environment for ASCs to proliferate and differentiate.  Multiple injections at appropriate 
times could be performed to slowly fill soft tissue defects. 
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2.1.1 Soft tissue reconstruction 
Tissue defects due to trauma, tumor resection, or congenital defects often require 
reconstruction.  The current options for breast reconstruction include prosthetics (saline or 
silicone implants), moving adipose tissue with a vascular supply (such as TRAM), or autologous 
fat graft.  Of these options, autologous fat grafting seems to be the most inviting. However, 
adipose tissue is not an effective filling material because of the insufficient vascularization once 
implanted and shrinkage/resorption over time.  Grafted fat tissue becomes resorbed over time 
with 10% surviving after two years.[36]  Microscopic examination demonstrates necrosis of 
adipocytes.  Furthermore, mature adipocytes do not readily proliferate.  Emerging research on 
autologous adult stem cells presents a potential innovative option for soft tissue reconstruction.   
2.1.2 Adipose derived stem cells (ASCs) 
Cell therapy is an integral area in regenerative medicine.  One of the most promising 
candidates for cell therapy is the autologous stem cell.  Investigators have found adult stem cells 
in various human tissues.  The use of autologous stem cells is promising due to the lack of 
immunological risk as well as minimal ethical conflicts.  Currently bone marrow has been the 
favored source of adult stem cells.  Autologous and allogenic bone marrow stem cells have been 
studied extensively.  Bone marrow consists of two populations of stem cells, hematopoietic 
(HSCs) and mesenchymal stem cells (MSCs)[37-39].  MSCs are multi-potent; they have the 
ability to differentiate into adipocytes, chondrocytes, myoblasts, and osteoblasts.[40, 41]  
However, bone marrow harvesting is painful and a potentially traumatic process.  As well, bone 
marrow results in a low yield of mesenchymal stem cells, less than 0.01% of cells from bone 
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marrow aspirates are stem cells [41].  Multi-potent stem cells have been found in adipose tissue 
(ASCs) by Zuk et al.[1, 2]  Adipose is a potentially abundant source of tissue that can easily be 
obtained.   Nathan et al. found adipose derived stem cells to be superior with respect to minimal 
donor site morbidity, easy procurement, less risk of contamination during ex vivo expansion, 
rapid growth rate, and availability[42].  
The differentiation of ASCs to all three germ layers has been examined.  ASCs have the 
ability to differentiate into many different cell types.  Figure 2-1 shows the different lineages 
ASCs have been differentiated into by various investigators (References in Appendix A).  The 
differentiation of ASCs down the mesenchymal lineage is well accepted; however, 
transdifferentiation down the endodermal and ectodermal lineages remains controversial. 
 
Figure 2-1. Plasticity of adipose derived stem cells. 
 
ASCs may also induce vascularization of tissues in vivo.  Hemmrich et al. have seen an 
increase in vascularization in scaffolds seeded with preadipocytes as compared to scaffolds 
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without cells[3, 43].  This may be due to the secretion of significant amounts of vascular 
endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and transforming growth 
factor-beta (TGF-β), and small amounts of fibroblast growth factor (FGF-2) and granulocyte 
macrophage-colony stimulating factor (GM-CSF) from ASCs; furthermore, in hypoxic 
conditions VEGF release is increased[44]. 
2.1.3 Adipogenesis of ASCs 
Adipose tissue is commonly found in subcutaneous loose tissue.  Visceral adipose tissue 
surrounds internal organs.  Adipose tissue is mainly composed of mature adipocytes.  However, 
adipose tissue also contains fibroblasts, smooth muscle cells, pericytes, endothelial cells, and 
adipose derived stem cells. The structure of adipose tissue is important to understand adipocyte 
differentiation.    Figure 2-2 is an overview of the stages in adipocyte differentiation, beginning 
with the stem cell and ending with a mature adipocyte.[45]   
 
Figure 2-2.  Adipocyte differentiation beginning with ASCs.[45] 
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Factors that induce adipocyte differentiation, adipogenic factors, include insulin, IGF-1, 
dexamethasone, cAMP, ciglitazone, and isobutyl-methylxanthine (IBMX).[46]  Two important 
transcription factors, CCAAT/enhancer binding protein-α (C/EBP-α) and peroxisome 
proliferator-activated receptor-γ (PPAR-γ), have been shown to activate adipocyte genes that are 
required for adipocyte differentiation.  PPAR-γ is the most specific to adipogenesis; it is induced 
before the transcriptional activation of most of the adipocyte genes.  In cell culture, growth arrest 
due to cell density is necessary for differentiation, in which both C/EBP-α and PPAR-γ are 
involved.[47]  Terminal differentiation is maintained by the expression of C/EBP-α and PPAR-γ, 
which act synergistically to activate transcription of genes.[46]   
2.1.4 Fibroblast growth factor-2 (FGF-2) 
A significant challenge in creating a large soft tissue mass is the limit of nutrients.  A 
vascular supply is required for cells to survive.  Controlled delivery of angiogenic factors at the 
site of implanted cells may promote survival and proliferation.  Fibroblast growth factor-2 (FGF-
2) is a growth factor known to induce angiogenesis and adipogenesis.  FGF-2, or basic FGF 
(bFGF) is a 16-25 kDa growth factor that stimulates the proliferation of many cell types 
including fibroblasts, myoblasts, osteoblasts, endothelial cells, and chondrocytes [48].  The 
controlled release of FGF-2 has been extensively studied, and Table 2-I lists some of the delivery 
systems examined.   
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Table 2-I. FGF-2 Delivery Systems 
Fibrin gel [49-51] Gelatin [52-58] 
Heparin gel [59] Apatic substrates [60] 
Hyaluronate-heparin [61] Gelatin microspheres [62-66] 
Glycosaminoglycan hydrogel [67] PLGA microspheres [68-70] 
Collagen hydrogel [71] Heparin-alginate microcapsules [72] 
Chitosan hydrogel [69, 73-75] PLGA microspheres in alginate [76] 
Dextran hydrogel [77] Gelatin microspheres in collagen [78, 79] 
Modified PEGDA [80] Heparin modified PEG [81] 
 
FGF-2 is also known for its angiogenic potential, due to its involvement by regulating the 
proliferation and migration of vascular endothelial cells[48]. The half life of FGF-2 has been 
reported as less than 50 minutes[82], 1.5 minutes, 4.5 minutes[83], and 3 minutes[84].  Even 
though these values differ, they are all relatively short. Due to its short half life, a delivery 
system is desired to maintain levels of FGF-2 in vivo.  Sustained release of FGF-2 has been 
reported as three times more potent than a bolus of FGF-2 to increase vascular endothelial and 
smooth muscle cell proliferation.[85]  FGF-2 increases capillary formation in vivo when 
compared to zero FGF-2.[63, 76, 86]  
FGF-2 increases adipose tissue formation in vivo.  Gelatin microspheres incorporating 
FGF-2 led to an increase in de novo induced adipogenesis and in situ adipogenesis of a rat fat 
pad versus free FGF-2.[63, 78, 79] Gelatin microspheres containing FGF-2 increased the 
formation of adipose tissue from preadipocytes seeded on collagen sponges.[65]   
The effects of FGF-2 on adult stem cells have been examined.  FGF-2 has been shown to 
increase mesenchymal stem cell (MSC) proliferation.[87-91]  The treatment of MSCs with FGF-
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2 induced adipogenesis with and without other differentiation components.[89, 92]  FGF-2 has 
induced the proliferation of ASCs[93-95] and induced adipogenesis of preadipocytes.[65, 96]  
The addition of FGF-2 has resulted in larger adipose tissue formation in vivo compared to 0 
FGF-2.[86]  Released FGF-2 results in a significantly higher adipogenesis of preadipocytes in 
vivo than free FGF-2.[65, 78]  In this study, we have chosen to focus on a controlled release of 
FGF-2 from polymer microspheres. 
2.1.5 Small intestinal submucosa scaffolds 
A critical element in tissue engineering is finding a suitable scaffold that promotes cell 
proliferation and differentiation. Naturally derived scaffolds may be advantageous due to 
properties such as biodegradability, biocompatibility, and the possibility to facilitate cell growth 
and proliferation.  The response of ASCs to natural scaffolds such as decellularized human 
placenta[97], hyaluronic acid[97-99], CultiSphers[100], fibrin[101-103], collagen[99, 104], 
decellularized vein grafts[105], and gelatin[103, 106, 107] have been studied.  Small intestinal 
submucosa (SIS) is a porcine derived extracellular matrix scaffold derived from the small 
intestinal submucosa.  SIS contains several angiogenic growth factors, rendering the extracellular 
matrix (ECM) scaffold successful for tissue remodeling.[108] SIS has primarily been used in 
hernia repair[109], but has also shown promising results as a scaffold for cell adhesion.[110, 
111]  SIS has supported the attachment and proliferation of NIH Swiss mouse 3T3 fibroblasts, 
NIH 3T3/j2 fibroblasts, primary human fibroblasts, primary human keratinocytes, human 
microvascular endothelial cells (HMECs), and an established rat osteosarcoma cell line.[112, 
113]  The interaction of SIS and mesenchymal stem cells has been studied.  Bone marrow 
stromal cells attach and proliferate on SIS without affecting their cellular activity and 
 17 
function.[114, 115]  The addition of SIS to MSCs in vivo has resulted in improvement of 
myocardial repair following infarction[116], bladder reconstruction in vivo[117], and 
osteogenesis in vitro.[114] SIS improved islet survival and function in vitro, leading to an 
increase in insulin secretion, and reduction of apoptosis.[118]  Muscle derived stem cells migrate 
into and distribute within SIS scaffolds and form contracting myotubes.[119]  Due to the 
promising results of these studies we have chosen to utilize SIS as our scaffold.   
2.1.6 Dexamethasone and delivery systems 
Dexamethasone (Dex) (Figure 2-3) is a synthetic corticosteroid with a radius of 6.5 
Angstroms.  Dex has most commonly been used to treat inflammation and auto-immune 
diseases.   
 
Figure 2-3. Structure of Dexamethasone   
 
Dexamethasone is an important factor in adipogenesis.  Dex has been shown to enhance 
adipogenesis by increasing the expression of C/EBP and PPAR-γ.[120, 121].   Dex is also 
responsible for preadipocyte recruitment.[120, 122, 123]  Adipogenesis by Dex alone has also 
been demonstrated.[88, 124]  However, an increase in adipocyte differentiation was seen with 
cells treated with both Dex and insulin, compared to either alone.[120] Dex is required to 
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establish a post-mitotic state of the ASCs, by distinguishing mitotic divisions of clonal expansion 
from those of logarithmic growth.[123] The addition of Dex increases cell differentiation 
compared to zero Dex.[124, 125] 
Although the release of Dex for use in adipogenesis of ASCs has not been examined, to 
the best of our knowledge, Dex has been released to induce osteogenesis of mesenchymal stem 
cells.[126]  However, due to the wide clinical applications of Dex, the controlled delivery of dex 
has been studied extensively.  Table 2-II lists some of the delivery systems that have been 
characterized.   
Table 2-II. Dexamethasone Delivery Systems 
Polymer micro/nanospheres [127-133] Poly(ortho ester) [134] 
Starch microspheres [135] Elastin-like polymer [136] 
Ethylcellulose microspheres [137] Si film [138] 
PLA-PEG film [139] Gelatin [140] 
PEG hydrogels [126, 128] Chitosan [131, 137] 
Polypyrrole [141] PLGA microspheres in PEG hydrogels [128] 
PLGA [142] PLGA microspheres in PVA hydrogels [143, 144] 
Polyurethane [145] PLGA microspheres in alginate[146] 
2.1.7 Insulin and delivery systems 
Insulin is a hormone that is secreted by the beta cells of the islets.  Insulin has been well 
studied because it stimulates cells to absorb glucose and amino acids from blood.  Patients with 
diabetes mellitus type I are treated with insulin, since their beta cells have been destroyed by 
their own bodies. Insulin is a peptide hormone composed of 51 amino acid residues with a 
molecular weight (MW) of ~6kDa. Insulin is another important adipogenic factor.  Insulin 
stimulates lipogenesis by enhancing the rate of lipid filling and enhancing the fraction of cells 
that differentiate.[147] 
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The release of insulin has been extensively investigated, mostly for treatment of diabetes.  
Table 2-III lists some of the delivery devices utilized to maintain release of insulin.   
Table 2-III.  Insulin Delivery Systems 
Polymer microspheres [148-157] PEG hydrogels [158-161] 
Chitosan microspheres [162-166] Chitosan hydrogels [167, 168] 
Gelatin microspheres [58, 169] Acrylic hydrogels [170] 
Hyaluronic acid microspheres [171] PLGA microspheres in PVA [172] 
Alginate-dextran nanospheres [173] Solid-lipid microparticles [174] 
 
More specifically, the release of insulin to induce adipogenesis has been demonstrated. 
Yuksel et al. showed that released insulin in vivo resulted in de novo adipose formation.[68]  
Similarly, insulin and IGF-1-loaded microspheres resulted in an increase in adipose flap weight 
at four weeks in vivo without adverse reactions to surrounding tissue.[175]  We are focusing on 
insulin release to induce adipogenesis of ASCs. 
In summary, our approach for soft tissue reconstruction focuses on the combination of 
injectable cells, scaffolds, and various growth factors.  We have seeded our ASCs on SIS 
particulate scaffolds and delivered FGF-2 from polymer microspheres to induce cell survival and 
proliferation in vivo.  We have also examined the induction of differentiation of ASCs due to 
released adipogenic factors, insulin and dexamethasone, in vitro.   
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2.2 METHODS 
2.2.1 Isolation of ASCs 
This study was conducted in accordance with the regulations of the Human Studies 
Committee of the University of Pittsburgh.  Tissue collection was performed according to a 
protocol approved by the University of Pittsburgh Institutional Review Board.  
The ASCs were isolated from fresh human abdominal adipose tissue harvested during 
elective surgery, as previously described.[176]  Adipose tissue was first treated with a 
collagenase (type II) solution and minced.  The tissue in the collagenase solution was then gently 
agitated at 37oC, filtered to remove large debris, and centrifuged.  The cellular pellet was 
resuspended in erythrocyte lysis buffer and centrifuged again.  The resulting cellular pellet was 
plated and cultured on tissue culture treated flasks in ASC plating medium (DMEM/F12, 10% 
FBS, 1% pen/strep, Dexamethasone). 
2.2.2 FGF-2 encapsulation and characterization 
PLGA microspheres were prepared using a double emulsion technique as previously 
described.[70]  FGF-2 (R&D Systems, Inc, Minneapolis, MN) was reconstituted in a heparin 
(1:1), EDTA (1:1), sucrose (5mg/25μg FGF-2), 0.1% BSA solution.  200mg of PLGA (75:25) 
(Lactel Absorbable Polymers, Pelham, AL) was dissolved in 1.8 mL methylene chloride (MC).  
To form the first emulsion, 50 µL of the 25µg/mL FGF-2 solution and 1 mL of 1% PVA solution 
were added to the dissolved PLGA and vortexed.  The first emulsion was then added to a stirring 
0.1% PVA solution and stirred at 900 rpm.  After five minutes, 100 mL of 2% isopropanol was 
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added dropwise and then stirred for 2 hours.  The microspheres were collected by centrifugation, 
frozen at -20oC, and freeze-dried.  Empty microspheres were also prepared using the same 
protocol, omitting the addition of FGF-2.   
Morphological characterization of the microspheres was examined using scanning 
electron microscopy (SEM).  The microspheres were gold coated using a Cressington 108 Auto 
(Cressington, Watford UK).  Microspheres were then viewed using a JSM-6330F scanning 
electron microscope (JEOL, Peabody, MA) operated at 10 kV accelerating.   
The release of FGF-2 from the microspheres was analyzed utilizing a commercially 
available Enzyme Linked Immunosorbent Assay (ELISA) kit (R&D).  Microspheres (10mg) 
were placed in a microcentrifuge tube containing 1 mL of Phosphate Buffered Solution (PBS) 
(n=5).  At various time points, the tubes were centrifuged and the supernatant collected, and then 
frozen at -80oC until analysis.  The samples were then refreshed with 1 mL PBS and vortexed for 
5 seconds.     
2.2.3 FGF-2 in vitro effects on ASCs 
The effects of FGF-2 concentration on ASC proliferation was investigated to determine 
the optimal concentration of FGF-2 to use in subsequent studies.  ASCs (30-35 year old female, 
abdominal deep, passage 2) were seeded at a density of 10,000 cells/mL per well of a tissue 
treated 24-well plate in ASC plating medium.  The cells were allowed to attach and proliferate 
for 24 hours.  The ASCs were then washed with PBS and treated with one of the experimental 
groups.  The experimental medium contained 0.5% FBS, 1% pen/strep, and Dexamethasone, 
except for the control that contained 10% FBS (ASC plating medium). The groups are as 
follows: 1) 10% FBS medium, 2) 0ng FGF-2, 3) 1ng FGF-2, or 4) 10ng FGF-2 (n=5 for each 
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group).  After 72 hours, the plates were washed with PBS, frozen, and analyzed utilizing 
CyQuant® (Molecular Probes, Eugene, Oregon)[177]. CyQUANT® is a fluorescence-based cell 
proliferation assay that utilizes a green fluorescent dye that binds to cellular nucleic acids. Viable 
cell number was calculated utilizing a standard curve.   
An in vitro study was performed to examine the effects of the FGF-2 microspheres on 
ASC proliferation.  ASCs (30-35 year old female, abdominal deep, passage 2) were seeded at a 
density of 3x105/mL into each well of a 24-well tissue culture plate in ASC plating medium.  
Cells were allowed to attach and proliferate for 24 hours.  The ASCs were then washed with PBS 
and treated with one of the following groups for 48 hours: 1) 0ng/mL FGF-2, 2) 1ng/mL free 
FGF-2, 3) FGF-2 microspheres releasing 1ng of FGF-2 over 48 hours, or 4) empty microspheres 
(n=5 for each group).  FGF-2 microspheres were suspended in Transwell® inserts above the 
attached ASCs.  The amount of microspheres added to each well was determined by calculating 
the microspheres necessary to release a total of 1ng of FGF-2 over 48 hours, thus a final 
concentration of 1ng FGF-2 per milliliter of media was obtained.  The wells were washed with 
PBS, frozen, and then the viable cell number was quantified utilizing CyQuant®.   
A longer in vitro study was performed to simulate a similar environment the cells would 
experience in vivo.  ASCs from three different patients, age range 30-45 years old and three 
different depots were utilized in this study.  The experiment was performed with ASCs from 
each of the following depots: 1) super abdominal, 2) deep abdominal, and 3) back.  ASCs were 
seeded at a density of 15x103 cells/mL into wells of a 24-well plate in plating medium and 
allowed to attach and proliferate for 48 hours.  All groups were then placed in experimental 
medium, containing no serum (DMEM/F12, 1% pen/strep, dexamethasone) for 24 hours.  After 
24 hours, cells were treated with one of the following groups, 1) 0ng/mL FGF-2 (control group), 
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2) 1ng/mL free FGF-2, 3) FGF-2 microspheres releasing a total of 1ng FGF-2 over 14 days, or 4) 
empty microspheres (n=5 for each group, repeated for each cell type).  The amount of FGF-2 
microspheres was the same amount that was used for the in vivo studies (21mg).  The medium 
was changed every other day for all groups.  The medium containing 1ng free FGF-2 was 
prepared on day 1, thus for the duration of the experiment the cells in the free FGF-2 group were 
treated every other day with 1ng FGF-2.  After 14 days, the plates were washed with PBS, 
frozen, and then the viable cell number was quantified utilizing CyQuant®.  
2.2.4 FGF-2 in vivo effects 
ASCs (30-35 year old female, abdominal deep, passage 5) were seeded on SIS particles 
(13 million cells on 0.16g SIS) utilizing a spinner flask (Bellco Glass, Vineyard, NJ) and 
incubated at 37ºC with 5% CO2 on a stir plate set to rotate at 15 rpm.  The ASCs were cultured in 
the spinner flask for 14 days before being utilized for the in vivo study.  The medium was 
changed in the spinner flask three times a week by allowing the SIS particles to settle and 
removing half of the medium and replacing it with fresh medium.  At various times points, SIS 
seeded particles were removed, fixed, and stained with DAPI, a fluorescent nuclear stain.  At the 
time of the procedure, syringes (1cc and 22G needles) for injection were prepared with 0.2mL of 
SIS and medium (DMEM/F12, 10% FBS).  Male athymic nude mice n=5 (for each group) (8 
weeks, 25 grams, Harlan, IN, USA) were anesthetized with isoflurane. The mice were injected 
with ASCs seeded on SIS as a control group.  The experimental groups included ASCs seeded on 
SIS and either 1) 1ng free FGF-2, or 2) FGF-2 microspheres (a total of 1 ng FGF-2 to be released 
over the 14 days, 21mg of microspheres).  The free FGF-2 and FGF-2 microspheres were 
injected subcutaneously (100 µL of DMEM/F12 as a carrier) along with the ASCs seeded on SIS 
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into the same site.  The injected areas were sutured with Vicryl 4-0, to ensure identification at the 
time of sacrifice.  On day 14, the animals were sacrificed.  Samples from the injected area, 
determined as the area enclosed by the sutures, were excised and divided in half.  One half was 
fixed in 10% buffered formalin and embedded in paraffin and the other half was frozen utilizing 
Optimal Cutting Temperature (OCT) compound.   
2.2.5 Histological analysis 
Samples embedded in paraffin were stained with hematoxylin and eosin (H&E) and 
adjacent sections for Factor VIII. The number of blood vessels within the injected area was 
quantified from H&E slides by three blind observers.  Each image was presented to an observer, 
and the number of evident blood vessels in the cross-section was manually counted.  Factor VIII 
staining was performed to verify the blood vessels present.   
The frozen sections were imaged for fluorescent analysis. The cells implanted in vivo 
were pre-labeled with Red Fluorescent Cell Linker, PKH26, (Sigma-Aldrich, Mo, USA). PKH 
Fluorescent Cell Linker Kits provide fluorescent labeling of live cells over an extended period of 
time, with no apparent toxic effects.[178, 179] PKH linker exhibits no significant leaking or 
transfer from cell to cell. PKH26, a red fluorochrome, has excitation (551 nm) and emission (567 
nm) characteristics compatible with rhodamine or phycoerythrin detection systems. The linkers 
are physiologically stable and show little to no toxic side effects on cell systems. Labeled cells 
retain both biological and proliferative activity, and are ideal for cell tracking studies.   
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2.2.6 Dexamethasone encapsulation and characterization 
Dexamethasone-sodium phosphate (Sigma Aldrich) PLGA microspheres (Dex MS) were 
prepared using a single emulsion/solvent extraction technique as previously described.  PLGA 
(75:25), 100mg, was dissolved in 4.5 mL MC.  Dex (20mg) was dissolved in 0.5mL methanol 
which was then added to the polymer solution.  This solution was then added to a stirring 0.2% 
PVA solution (600mL) and stirred at 1200 rpm for two hours.  The microspheres were collected 
by centrifugation, frozen at -20oC, and freeze-dried.  Empty microspheres were also prepared 
using the same protocol, omitting the addition of Dex.  Morphological characterization of the 
microspheres was examined using SEM as previously described.   
The release of Dex from the microspheres was analyzed spectrophotometrically at 
242nm.  Microspheres (10mg) were placed in a microcentrifuge tube containing 1 mL of PBS 
(n=5).  At various time points, the tubes were centrifuged, the supernatant collected, and then 
frozen at -80oC until analysis.  The samples were refreshed with 1 mL PBS and vortexed.  The 
amount of Dex released was determined by comparison to a standard curve.  
The following equations were used to characterize the microspheres:  
w
E
S
DLC =   Equation 2-1 
%100×=
Pf
Pi
M
MYield  Equation 2-2 
In equation 2-1, LC is the loading capacity, which determines the amount of drug per 
weight of microspheres.  Where, DE is the amount of drug encapsulated and Sw is the mass of the 
microspheres.  The yield is calculated by equation 2-2, where MPi is the initial mass of polymer 
used to fabricate the microspheres and MPf is the final mass of the microspheres.   
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The encapsulation efficiency was determined by a method previously described by Sah et 
al.[180]  Briefly, 20mg of microspheres were dissolved in 2mL DMSO for 1 hour.  Then 10mL 
of 0.05N NaOH containing 0.05w/v% SDS solution was added for 1 hour.  The amount of Dex 
in the resulting solution was assessed as mentioned above, spectrophotometrically.   
2.2.7 Insulin encapsulation and characterization 
 Insulin loaded PLGA microspheres (Insulin MS) were prepared using a double 
emulsion/solvent extraction technique as previously described.  400mg of PLGA (75:25) was 
dissolved in 2.0 mL methylene chloride (MC).  To form the first emulsion, 15mg of insulin 
(Sigma) was dissolved in 0.2mL of PBS, which was then added to the dissolved PLGA and 
vortexed.  The first emulsion was added to a stirring 100mL of 2.0% PVA solution and stirred at 
500 rpm.  After 2 min, 400 mL of water was added and then stirred for 3 hours at 500rpm.  The 
microspheres were collected by centrifugation, frozen at -20oC, and freeze-dried.  Empty 
microspheres were also prepared using the same protocol, omitting the addition of insulin.  The 
microspheres were morphologically characterized using SEM as previously described.   
The released insulin was analyzed utilizing FluoroProfile Protein Quantification Kit 
(Sigma Aldrich, St Louis, MO).   Microspheres (10mg) were placed in a microcentrifuge tube 
containing 1 mL of PBS (n=5).  At various time points, the tubes were centrifuged, the 
supernatant collected, and then frozen at -80oC until analysis.  The samples were refreshed with 
1 mL PBS and vortexed.    For analysis, 50µL of the sample and 50µL of the working reagent 
were added to a black 96 well plate and the fluorescence was measured at 485nm excitation and 
635nm emission.  
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The yield and loading capacity were calculated as mentioned above (section 2.2.6).  The 
encapsulation efficiency was determined as mentioned above (section 2.2.6).  The amount of 
insulin in the resulting solution was assessed utilizing a BCA kit (Pierce, Rockford, USA).   
2.2.8 In vitro effects of released dexamethasone and insulin on ASC differentiation 
The optimal weight of microspheres to induce ASC adipogenesis was determined for 
subsequent studies.  According to the release study, 4mg of dexamethasone and 5mg of insulin 
microspheres would achieve the desired released adipogenic factors.  To further assess this, three 
different amounts of each microsphere type was assessed, x, 2x, and 5x.   
ASCs (female, super abdominal, 35-40 years old, passage 2) were seeded into tissue 
culture treated 12-well plates at a density of 50,000 cells/mL.  The cells were allowed to adhere 
and proliferate for seven days in ASC plating medium.  The cells were then treated for fourteen 
days in various treatment groups.  The negative control group was treatment with DMEM/F12 
medium containing 1%pen/strep (n=6).  The positive control group was treatment with 
differentiation medium, DMEM/F12 with 1% pen/strep containing differentiation components 
(22µM biotin, 17µM D-pantothenic acid; 1.0µM ciglitazone, 0.2nM T3, 10mg/L transferin, and 
540µM IBMX (IBMX for first 48 hours only)), and 0.5µM insulin, and 0.2nM dexamethasone  
(Diff medium)(n=6).    
The combined effects of Dex and insulin MS were assessed.  Cells were treated with Diff 
medium containing 0 insulin and 0 dexamethasone (Diff components + 0 insulin + 0 
dexamethasone) (Diff-Dex-Ins medium).  The treatment group was treated with the same 
medium (Diff-Dex-Ins medium) plus 4mg, 8mg, or 20mg Dex MS plus 5mg, 10mg, or 25mg 
 28 
insulin MS.  ASCs in the negative control medium were also treated with 4mg, 8mg, or 16mg 
Dex MS plus 5mg, 10mg, or 25mg insulin MS.   
2.2.9 Differentiation of ASCs utilizing dexamethasone and insulin microspheres 
To further assess the ability of Dex and insulin MS to replace Dex and insulin in medium, 
the optimal amount of microspheres previously demonstrated were used for all subsequent 
studies.  A similar study as described above was performed.  ASCs (female, back, 40-45 yo, 
passage 1) were seeded into tissue culture treated 6-well plates at a density of 200,000 cells/mL.  
The cells were allowed to adhere and proliferate for seven days in ASC plating medium.  The 
cells were then treated for fourteen days in various treatment groups.   
The effects of the dexamethasone microspheres on ASC differentiation were examined 
by comparing treatment of cells with Diff medium containing 0 dexamethasone (Diff 
components + 0.5µM insulin + 0 dexamethasone) (Diff-Dex medium) with cells in the same 
medium (Diff-Dex medium) plus 8mg of  Dex MS.   
To determine the effects of insulin microspheres on ASC adipogenesis, cells were treated 
with Diff medium containing 0 insulin (Diff components + 0 insulin + 0.2nM dexamethasone) 
(Diff-insulin medium).  The adipogenesis was compared to cells treated in the same medium 
(Diff-insulin medium) plus 10mg insulin MS.  
The combined effects of Dex and insulin MS were assessed in a similar manner.  Cells 
were treated with Diff medium containing 0 insulin and 0 dexamethasone (Diff components + 0 
insulin + 0 dexamethasone) (Diff-Dex-Ins medium).  The treatment group was treated with the 
same medium (Diff-Dex-Ins medium) plus 8mg Dex MS plus 10mg insulin MS.  ASCs in the 
negative control medium were also treated with 8mg Dex MS plus 10mg insulin MS.  As a 
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further control, empty MS were added to cells treated in the negative control medium.  The 
treatment groups were as summarized in the following table.  
Table 2-IV. Treatment Groups with Dexamethasone and Insulin Microspheres 
Treatment Group DMEM/F12 Diff Components Dex Insulin Dex MS 
Insulin 
MS 
Negative Control X      
Positive Control X X X X   
Diff - Dex X X  X   
Diff – Dex + Dex MS X X  X X  
Diff - Insulin X X X    
Diff - Insulin + Insulin MS X X X   X 
Diff - Dex – Insulin X X     
Diff – Dex – Insulin + Dex 
MS + Insulin MS X X   X X 
+ Dex MS + Insulin MS X    X X 
Empty MS X      
2.2.10 Oil red O staining 
After 14 days of treatment, the ASCs were washed with PBS, fixed in a 10% buffered 
formalin solution for 10 minutes, washed with DI water (two times), and stained with Oil red O 
for 30 minutes, then washed with water.  The ASCs were then imaged under light microscopy.  
Four fields of view per well were imaged to determine the number of cells with lipid inclusions 
per field of view.  All values were normalized to the positive control.   
2.2.11 Western blot analysis 
Cell lysates were collected following fourteen days of treatment.  Cells were first washed 
with PBS and then 100µL of lysis buffer (m-PER, Pierce, Rockford, IL) and proteinase inhibitor 
(1:100 dilution, Sigma Aldrich, St. Louis, MO) were added to each well.  The protein solutions 
were frozen at -80oC until analysis. Total protein was measured using the BCA Protein Assay 
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Kit. Equal amounts of protein from each sample were loaded into a 10% SDS-PAGE gel for gel 
electrophoresis.  The separated proteins were then transferred to a nitrocellulose membrane.  The 
membrane was blocked in 5%milk/PBS/Tween-20 for 2 hours and then the primary antibody 
(PPAR-γ, Santa Cruz, Santa Cruz, CA) in 1%milk/PBS/Tween-20 was applied overnight at 4oC.  
The secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) in 
1%milk/PBS/Tween-20 was applied for 1 hour. The proteins present on the membrane were 
detected using the ECL Plus detection system (Amersham, Piscataway, NJ).  Expression of 
GAPDH was used as an internal control.   
2.2.12 Statistical analysis 
All values are reported as means ± standard deviations.  ANOVA was used for 
comparisons between groups. In vitro experiments with two groups were compared using t-test 
analysis. Differences were significant when p<0.05. 
2.3 RESULTS 
2.3.1 FGF-2 characterization 
We have encapsulated FGF-2 into PLGA microspheres.  Figure 2-4 depicts the FGF-2 
microspheres using scanning electron microscopy (SEM).  SEM was also utilized to determine 
the morphology and diameter of the microspheres.  The microspheres exhibit a smooth round 
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morphology.  The diameter of the microspheres ranged from 1µm to 65µm (Figure 2-5), the 
average diameter of the microspheres was 9.19 ± 9.51 µm.   
 
Figure 2-4. SEM of FGF-2 microspheres.[181] 
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Figure 2-5. Diameter distribution of FGF-2 microspheres.[181] 
The release of FGF-2 from the microspheres was determined using an ELISA kit.  FGF-2 
was released over 14 days (Figure 2-6).  The majority of the FGF-2 was released within the first 
day; 96% was released in the first 24 hours.  The remaining 4% was released over the following 
13 days.    
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Figure 2-6. Percent cumulative release of FGF-2 from PLGA microspheres. 
2.3.2 Effects of FGF-2 on ASCs in vitro 
The optimal concentration of FGF-2 to induce ASC proliferation was determined.  FGF-2 
at a concentration of 0, 1, and 10ng/mL was examined.  A significant increase in cell 
proliferation was seen in all groups compared to 0ng FGF-2 (Figure 2-7).  There were no 
significant differences between the 1ng/mL and the 10ng/mL group.  Since increasing the 
amount of FGF-2 to 10ng did not result in a significant increase, and the trend showed more 
proliferation in the 1ng/mL group, 1ng/mL FGF-2 was used for all subsequent studies. 
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Figure 2-7. Viable ASCs after treatment for 72 hours.   
(n=5) *p<0.05 compared to 0ng FGF-2. 
 
Transwell® inserts and CyQuant® were utilized to determine the effects of FGF-2 on 
ASC proliferation.  The ASCs were treated with 1 ng free FGF-2, FGF-2 microspheres (releasing 
a total of 1 ng FGF-2 over 48 hours), or empty microspheres.  A significant increase in cell 
proliferation was seen with the addition of 1 ng of free FGF-2 (p=0.031).  A slight increase in 
cell proliferation was seen in the group treated with FGF-2 microspheres, when compared to 
media alone (p=0.056) (Figure 2-8).   
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Figure 2-8. Viable ASCs after treatment for 48 hours.   
*p<0.05, #p<0.10[181] 
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A longer in vitro study was performed over 14 days to determine the effect of the FGF-2 
microspheres and free FGF-2 on the ASCs (Figure 2-9).  All groups were treated with medium 
containing no serum.  Cell survival was significantly increased in the group treated with the 
FGF-2 microspheres compared to all groups (Figure 2-9).  The cells treated with 1ng/mL free 
FGF-2 at each feeding were not significantly different from cells in the control group.  There was 
also no significant difference between cells treated with empty microspheres when compared to 
those in the control group (0ng FGF-2).  The FGF-2 microspheres resulted in an increase in ASC 
survival and proliferation in the absence of serum.  These results were consistent among the three 
types of ASCs.   
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Figure 2-9. Viable ASCs after 14 days in vitro.  
*p<0.05[181] 
2.3.3 Effects of released FGF-2 on ASCs in vivo 
ASCs were labeled with PKH26 and seeded onto SIS particles and injected 
subcutaneously into nude mice (Figure 2-10).   Two groups of mice were then given an 
additional injection of either 1 ng of free FGF-2 or FGF-2 microspheres, releasing a total of 1 ng 
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FGF-2 over the 14 days.  The third group was not treated with any further injections (n=5 for 
each group). 
 
Figure 2-10.  ASCs seeded on SIS particle (a).  Injection sites on the back of mouse (b).[181] 
 The mice were sacrificed after 14 days; sections were embedded in paraffin and stained 
with H&E and Factor VIII.  Cell survival was determined by locating the PKH26 labeled cells.  
Figure 2-11b depicts the PKH26 labeled cells and the corresponding H&E staining (Figure 2-
11a) from a mouse treated with FGF-2 microspheres.  Cells survived in all three groups.  Factor 
VIII staining was performed to confirm the presence of blood vessels.  Representative images of 
H&E and the corresponding Factor VIII staining for each group are shown in Figure 2-12.  The 
arrows in the H&E images denote the injection site of ASC seeded SIS particles (a,c,e).  The 
arrows denote staining of blood vessels (b,d,f).  A vascular network surrounding the injected area 
could be seen in mice treated with FGF-2 microspheres (Figure2-13a). The number of blood 
vessels in the injection area was quantified from H&E images (Figure 2-13b).  The mice that 
received the injection of FGF-2 microspheres had a significant increase in the number of blood 
vessels present.  
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 Figure 2-11.  ASCs present after 14 days in vivo. 
H&E staining of ASC and SIS injection area (100x) (a) PKH26 labeled ASCs 14 days after injection (400x) 
(b). [181] 
 
 
Figure 2-12.  H&E and corresponding Factor VIII images 100x.  
 FGF-2 microsphere injection (a and b), free FGF-2 injection (c and d), and control (0 FGF-2) (e and f).  
Arrows in H&E images denote site of injection.  Arrows in Factor VIII images denote blood vessels.[181] 
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Figure 2-13.  Image depicting vascularization in mouse treated with FGF-2 microspheres (a).  Boxplot of 
number of blood vessels surrounding injection area (b).[181] 
2.3.4 Dexamethasone microsphere characterization 
Dex microspheres were examined by SEM (Figure 2-14).  The microspheres had an 
average diameter of 10 µm.  The diameter distribution of the Dex MS is shown in Figure 2-15.  
The release of dexamethasone occurred over 52 days (Figure 2-16).   A controlled release was 
maintained.  After one day 28.4 ± 5.3% of total dexamethasone released was released.  A large 
burst effect was not observed, which is most likely due the hydrophobic nature of 
dexamethasone.  After 48 days, 96.0 ± 1.3% was released.  The yield was 70.3 ± 12.6%.  The 
loading capacity was 7.24 ± 1.48µg Dex per mg of microspheres. 
 
Figure 2-14.  SEM of dexamethasone microspheres. 
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Figure 2-15.  Diameter distribution of dexamethasone microspheres. 
Results expressed as means ± standard deviations. 
 
 
Figure 2-16.  Cumulative release of dexamethasone per milligram of microspheres. 
Results expressed as means ± standard deviations (n=8). 
2.3.5 Insulin microsphere characterization 
Insulin microspheres were examined utilizing SEM (Figure 2-17).  The average diameter 
of the insulin microspheres was 272 µm (Figure 2-18).  The release of insulin was maintained 
over 52 days (Figure 2-19).    The insulin microspheres yield was 35.6±10.8%.  The loading 
capacity was 11.6 ± 2.3 µg insulin per mg of microspheres. 
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 Figure 2-17.  SEM of insulin microspheres. 
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Figure 2-18.  Diameter distribution of insulin microspheres. 
 
Figure 2-19.  Percent cumulative release of insulin.   
All points are reported as means ± standard deviations (n=8). 
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2.3.6 Effects of dexamethasone and insulin microspheres on ASC differentiation 
To determine the optimal amount of microspheres required to induce differentiation, 
three different weights of each type of microsphere was examined.  The combination of the 
microspheres in negative control medium showed the most differentiation with 8mg 
dexamethasone and 10mg insulin, as noted by Oil red O staining (Figure 2-20c).  The group 
treated with 4mg and 5mg of dexamethasone and insulin microspheres resulted in some 
differentiation, but more was seen in the 8 and 10mg group (Figure 2-20b).  The ASCs in the 
group treated with 20mg dexamethasone and 25mg insulin microspheres appear to have died 
(Figure 2-20d).  This is most likely due to such a large dose of the adipogenic factors.   
 
Figure 2-20.  Oil Red O staining of ASCs.   
ASCs treated with negative control medium (a), negative control medium + 4mg dexamethasone MS + 5mg 
insulin MS (b), negative control medium + 8mg dexamethasone MS + 10mg insulin MS (c), negative control 
medium + 20mg dexamethasone + 25mg insulin MS (d). 
 
These effects are even more apparent under light microscopy in the groups treated with 
Diff-Dex-Insulin medium.  With the addition of 4mg Dex and 5mg insulin MS, some 
differentiation has occurred (Figure 2-21b).  Again, it appears as though the ASCs were dying in 
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the group treated with the largest amount of microspheres (Figure 2-21d).  The best 
differentiation occurred in the group treated with the 8mg Dex and 10mg insulin MS (Figure 2-
21c). 
 
Figure 2-21.  Light microscopy of ASCs. 
ASCs treated with Diff-Dex-Ins medium (a), Diff-Dex-Ins medium + 4mg Dex MS + 5mg insulin MS (b), Diff-
Dex-Ins + 8mg Dex MS + 10mg insulin MS (c), and Diff-Dex-Ins medium + 20mg Dex MS + 25mg insulin MS 
(d). 
2.3.7 Effects of released dexamethasone in vitro 
To assess the ability of Dex MS to replace dexamethasone in media we examined the 
differentiation of ASCs following treatment with 8mg of dexamethasone microspheres.  Little to 
no differentiation could be detected by Oil red O staining in the groups treated with the negative 
control (DMEM/F12 medium) or the ASCs treated with Diff-Dex medium (Figure 2-22a and c).  
However, differentiation of the ASCs did occur in the group treated with Dex MS (Figure 2-
22d).  The same results were seen by the quantification of cells with lipid inclusions per field of 
view (Figure 2-23).  However, the results demonstrated no difference in PPAR-γ expression 
between cells treated with Diff-Dex medium and Diff-Dex medium + Dex MS (Figure 2-24). 
 42 
 Figure 2-22.  Oil Red O Staining after treatment with Dex groups.  
Oil Red O staining of ASCs treated with negative control medium (a), positive control medium (Diff medium) 
(b), Diff-Dex medium (c), Diff-Dex medium + Dex MS (d). 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
DMEM/F12 (Neg.
Control)
Diff Media  -
Dex
+ Dex MS Diff Media (Pos.
Control)
C
el
ls
 w
ith
 li
pi
d 
in
cl
us
io
ns
/fi
el
d 
of
 v
ie
w
 
(n
or
m
al
iz
ed
)
*
**
 
Figure 2-23.  Quantification of ASCs with lipid inclusions per field of view after treatment with Dex groups.   
*p<0.05 compared to negative control and Diff Media-Dex, **p<0.05 compared to all groups (n=6 or 5). 
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 Figure 2-24.  PPAR-γ expression in ASCs treated with Diff-Dex medium and Diff-Dex medium + Dex MS.   
GAPDH shown as a loading control. 
2.3.8 Effects of released insulin in vitro 
The effectiveness of insulin microspheres to replace insulin media was also examined.  
The group treated with the Diff-Insulin media resulted in some adipogenesis of the cells; 
however, with the addition of insulin microspheres many more cells differentiated (Figure 2-25 c 
and d).  With the addition of the insulin microspheres, there was no statistical difference 
compared to the positive control group (Figure 2-26).  Expression of PPAR-γ was increased in 
the group treated with insulin microspheres, compared to no insulin (Figure 2-27). 
 
Figure 2-25.  Oil Red O staining of ASCs treated with Insulin groups.   
Negative control medium (a), positive control medium (b), Diff-Insulin medium (c), Diff-Insulin medium + 
insulin MS (d). 
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Figure 2-26.  Number of ASCs with lipid inclusions per field of view in insulin groups.   
*p<0.05 compared to negative control and Diff Media-Insulin (n=5 or 6). 
 
 
Figure 2-27.  PPAR-γ expression in ASCs treated with Diff-Insulin medium and Diff-Insulin medium + 
insulin MS.   
GAPDH used as a loading control. 
2.3.9 Combined effects of released dexamethasone and insulin in vitro 
The effects of both the released dex and insulin were examined in combination with 
medium containing differentiation components and without.  Cells treated in medium containing 
the differentiation components but 0 insulin and 0 dex resulted in almost no differentiation.  With 
the addition of dex and insulin MS, many more cells stained positive for Oil red O (Figure 2-28 c 
and d).  Again the number of cells with lipid inclusions per field of view were quantified (Figure 
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2-29).  The positive control had significantly more cells with lipid inclusions than any of the 
other groups.  The group treated with the dex and insulin microspheres also had a significant 
increase in cells with lipid inclusions compared to no microspheres and the negative control 
group.  The western blots demonstrated a slight increase in PPAR-γ expression in the group 
treated with both the dex and insulin MS (Figure 2-30). 
 
Figure 2-28.  Oil Red O staining of ASC of ASCs treated with Dex and Insulin groups. 
Negative control medium (a), positive control medium (b), Diff-Dex-Insulin medium (c), Diff-Dex-Insulin 
medium + Dex MS + insulin MS (d). 
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Figure 2-29.  Number of ASCs with lipid inclusions per field of view in Dex and Insulin groups. 
  *p<0.05 compared to negative control and Diff Media-Dex-Insulin, **p<0.05 compared to all other groups 
(n=5 or 6). 
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 Figure 2-30.  PPAR-γ expression in ASCs from Diff-Dex-Insulin medium and Diff-Dex-Insulin medium + Dex 
MS + insulin MS.  
GAPDH used as an internal loading control. 
 
Dex and insulin microspheres were added to cells treated in the negative control medium.  
Adipogenic differentiation did occur, with cells staining positive for Oil red O (Figure 2-31d).  
Even though this group had significantly more cells with lipid inclusions over the negative 
control, it also had significantly less than the positive control (Figure 2-32).  A control of empty 
microspheres from both microsphere protocols was added to cells treated with the negative 
control medium.  The empty microspheres did not have an effect on ASC differentiation, as very 
little differentiation was observed (Figure 2-31c). 
 
Figure 2-31. Oil Red O staining of ASCs treated with empty microspheres and Dex and Insulin. 
Negative control medium (a), positive control medium (b), Empty MS(c), negative control medium + Dex MS 
+ insulin MS (d). 
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Figure 2-32.  Number of ASCs with lipid inclusions per field of view with Dex and Insulin microspheres alone. 
 *p<0.05 compared to negative control, **p<0.05 compared to all other groups (n=5 or 6). 
2.4 DISCUSSION 
The current therapeutic options for soft tissue reconstruction have inherent problems.  
These options include autologous tissue flaps, which are highly invasive and may lead to donor 
site morbidity; prosthetic implants, which pose problems of capsular contracture and device 
failure over time; and materials derived from mammalian tissue, such as acellular human dermis, 
which are subject to resorption. Autologous cell-based therapies have potential for soft tissue 
reconstruction.  One such cell source can be derived from liposuctioned or whole fat and readily 
expanded in culture, termed preadipocytes, or adipose-derived stem cells.  These cells can 
tolerate the mechanical trauma of the harvest techniques better than mature adipocytes.[182] 
Moreover, these cells can be easily differentiated into mature fat cells in vitro using a defined 
inductive medium.    
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 In this study, we examined the effects of FGF-2 microspheres on ASC survival and 
proliferation in vitro.  The FGF-2 microspheres resulted in an increase in cell survival and 
proliferation over groups treated with free FGF-2 (p<0.01) and no FGF-2 (p<0.01) over 14 days 
in vitro.  The effects of FGF-2 on mesenchymal stem cells have been well studied.  Solchaga et 
al. examined the mitotic effects of FGF-2 on bone-marrow MSCs and found similar results to 
ours.[90] As well, Hankemeier et al. found that a lower dose of 3ng/mL FGF-2 resulted in 
increased proliferation in bone marrow MSCs over 30ng/mL FGF-2.[91]   Kakudo et al. 
examined the effects of FGF-2 on ASCs during different phases.  They found by adding FGF-2 
to medium during the proliferation phase, adipogenesis was increased.[183]  This is most likely 
due to the increase in cell proliferation and thus resulting in cell arrest, which as mentioned 
before, is important in adipogenesis.   
 Based on our in vitro results, we chose to examine the effect of FGF-2 microspheres 
in vivo.  We examined the effect of released FGF-2 on vascularization of the ASC/SIS construct.  
FGF-2 is a known powerful angiogenic growth factor. Our results demonstrate that 
vascularization is indeed increased due to the controlled release of FGF-2 from the 
biodegradable PLGA microspheres (p<0.05).  Others have examined the role of FGF-2 in 
angiogenesis, as well as the release of FGF-2 from microspheres. Perets et al. examined in vivo 
angiogenesis after implantation of PLGA FGF-2 loaded microspheres in alginate composite 
scaffolds and saw an increase in capillary density as well as the size of vessels over empty 
scaffolds.[76]  Similarly, Sakakibara et al. showed the release of FGF-2 from gelatin 
microspheres resulted in an increase in neovessels surrounding the injection area.[66] Masuda et 
al. examined the effects of varying amounts of FGF-2 (0.01, 0.1, 1, and 10µg) in Wistar rats 
subcutaneously.  After two weeks, neovascularization was increased in all FGF-2 groups 
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compared to rats treated with no FGF-2.[58]  At four weeks, no difference in capillary density 
could be seen between the groups, except the lowest dose of FGF-2 (0.01µg) was greater than 
the control (0µg FGF-2).[58] These results are consistent with our lower dose of FGF-2 
(1ng/mL).   
 The effects of FGF-2 on vascularization in areas of adipogenesis have also been 
studied. Recently, Vashi et al. studied the controlled release of FGF-2 from collagen matrices as 
related to adipose formation in a mouse tissue engineering model.[79] Tabata et al. showed 
similar results to our study.  De novo adipose tissue formation and capillary formation were 
examined after implanting matrigel with FGF-2 loaded gelatin microspheres subcutis in BALB/c 
mice.  After six weeks, capillary formation was significantly greater in mice treated with FGF-2 
gelatin microspheres over free FGF-2 or empty microspheres.[63]  Some discussion has been 
invoked about whether or not the vascularization is due to a foreign body response to the 
microspheres.  However, this has been examined by many other researchers.  No inflammatory 
response to PLGA/PEG microspheres was seen in a study by Yuksel et al.[175]  Kang et al. 
observed an initial inflammatory response after injection of PLGA microspheres, but no long 
term effects were seen.[150]  The inflammation is believed to be due to trauma of injection, 
which is present with or without microspheres.  These results further validate that the 
neovascularization seen in our study was due to released FGF-2 and not a foreign body response.   
 Many have examined the potential of preadipocytes or ASCs to form adipose tissue in 
vivo.  In our study, our cells did survive; however, we did not see a large adipose tissue mass 
after two weeks in vivo.  Others have seen similar results.  For example, Choi et al. recently 
evaluated adipogenesis in vivo utilizing MSCs attached to PLGA microspheres.[184] Their 
results demonstrated that if the MSCs were pre-treated with adipogenic media prior to injection, 
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there was substantially more adipose tissue formation.  The group that was not pretreated 
resulted in little to no lipid containing cells after two weeks in vivo.[184]  Similar results were 
seen by Lee et al. with ASCs.  The adipogenesis of ASCs seeded on poly(glycolic acid) (PGA) 
scaffolds implanted overlying the skull of Lewis rats was examined.  ASCs received treatment 
with either control or adipogenic medium for 7 days prior to implantation.  After four and eight 
weeks, adipose tissue was present in the adipogenic induced scaffolds and absent in the ASC 
group.[185] Hemmrich et al. seeded preadipocytes on hyaluronic sponges which resulted in no 
fat formation at three, eight, or twelve weeks in vivo in nude mice.[43]  While these groups did 
not examine the delivery of growth factors to induce differentiation, others have examined the 
delivery of FGF-2.  Kimura et al. reported after six weeks in vivo, collagen sponges seeded with 
preadipocytes and FGF-2 gelatin microspheres resulted in adipogenesis; significantly less 
adipogenesis was seen with the addition of free FGF-2.[65]  Hiraoka et al. implanted 
preadipocyte-seeded collagen scaffolds with FGF-2 incorporated gelatin microspheres in mice 
within the fat pad.  At two weeks, cells were present, but no mature adipocytes were present.  
However, lipid accumulation was seen at 4 and 6 weeks.[78]  These results indicate that had our 
in vivo study gone on longer we might have seen adipose tissue formation.  It may also indicate 
that other adipogenic factors may be necessary to induce adipogenesis.   
 We continued to assess the ability of ASCs for soft tissue reconstruction by 
examining the release of adipogenic factors, insulin and dexamethasone, to induce 
differentiation.  We successfully encapsulated dex and insulin in PLGA microspheres.  We did 
not see a burst release from the dex microspheres and maintained the release for over 50 days.  
These results were in accordance with Yoon et al. They also did not see a burst effect from 
PLGA scaffolds and maintained a release over 30 days.[142] We saw an initial burst release 
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from the insulin microspheres, an average of 50% of the total insulin released over 52 days was 
released on the first day.  Similarly, Ibrahim et al. saw an initial burst of 71% from insulin loaded 
PLGA microspheres.[149] 
  Researchers have examined the effects of released insulin on adipose tissue 
formation.  Masuda et al. examined the de novo adipogenesis in rats injected with combinations 
of gelatin microspheres containing FGF-2, insulin, and insulin-like growth factor-1 (IGF-1) 
subcutaneously.  Their results showed that the largest amount of adipogenesis occurred with the 
combination of insulin, IGF-1, and FGF-2 as well as with the combination of insulin and IGF-
1.[58]  Yuksel et al. reported the release of IGF-1 as well as insulin from PLGA microspheres 
(combined with polyethylene glycol) enhanced de novo adipose tissue formation.[186]  Their 
study demonstrated the potential of long-term local insulin and IGF-1 delivery to induce 
adipogenic differentiation to mature lipid-containing adipocytes from non-adipocyte cell pools 
that were administered directly to the deep muscular fascia of the rat abdominal wall.  However, 
to the best of our knowledge no one has examined the release of dex and insulin from PLGA 
microspheres to induce adipogenesis of ASCs.  In this study, we demonstrated that ASC 
differentiation could be induced by released dex and insulin.  The insulin loaded microspheres 
successfully replaced insulin in media.  There were no significant differences in the number of 
cells that had differentiated compared to the positive control.  PPAR-γ expression was markedly 
increased compared to treatment without insulin.  However, the results for the dexamethasone 
loaded microspheres were not as successful.  Although there was a statistical difference 
compared to zero dexamethasone, the number of cells with lipid inclusions was significantly 
decreased compared to the positive control.  The expression of PPAR-γ did not seem to increase 
or decrease compared to treatment without dexamethasone.  More studies should be performed to 
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optimize the amount of microspheres necessary to better induce differentiation.  Preliminary 
studies were performed at three different amounts of dex microspheres, 4, 8, and 20mg, which 
resulted in 8mg being optimal.  However, there may be a more optimal amount between 8 and 
20mg of dex microspheres.  
2.5 CONCLUSIONS 
In our study, we aimed to enhance ASC survival and adipogenesis.  We improved 
vascularization of the implanted ASC/SIS constructs by injecting PLGA microspheres 
encapsulating FGF-2.  Our results demonstrated that the number of blood vessels surrounding the 
implant after two weeks was significantly higher when compared to both implants without FGF-
2 (control) and also simple injection of free FGF-2.  We did not see a difference in cell survival 
or adipogenesis at this point.    
We induced differentiation of ASCs in vitro, by replacing dex and insulin in media with 
released adipogenic factors from PLGA microspheres.  The number of cells with lipid inclusions 
was significantly increased compared to the negative control and to controls lacking the 
adipogenic factors.   
This finding has implications for new clinical therapies in soft tissue reconstruction.  An 
injectable engineered soft tissue replacement can be used to reconstruct a defect, but would have 
to be administered in serial treatments and will depend on successful vascularization of the 
cell/scaffold construct before more material can be added.  Including FGF-2 microspheres with 
the cells and scaffold mixture would not only enhance survival of the implanted cells, but could 
decrease the time required for successful vascularization and accelerate the treatment process.  
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These injections could be followed by dex and insulin microspheres to enhance adipogenesis of 
the cells.  
2.6 FUTURE EXPERIMENTS 
We have successfully completed our aim to encapsulate factors to enhance and induce 
differentiation of ASCs.  Future studies must be performed to demonstrate their potential for soft 
tissue reconstruction.   Longer studies in vivo must be done to determine if the FGF-2 
microspheres will have an effect on cell survival and adipogenesis.  Since we did not achieve 
differentiation at a desired level from the dexamethasone microspheres, more in vitro studies 
should be performed to optimize the amount of microspheres necessary.  Furthermore, induction 
of differentiation with insulin and dexamethasone microspheres alone resulted in minimal 
adipogenesis in vitro.  Other adipogenic factors may be necessary to obtain optimal 
differentiation.  From studies within our lab, ciglitazone, a PPAR-γ agonist, has been shown to 
be an important adipogenic factor.  Another important factor may be IBMX, a cAMP enhancer.  
Finally, in vivo studies including all of the adipogenic microspheres, with possible multiple 
injections of microspheres and cell-seeded particles should be performed.   
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3.0  CONTROLLED RELEASE OF CHEMOTHERAPY FROM PLGA 
MICROSPHERES/GELATIN SCAFFOLDS AS ADJUVANT THERAPY FOR BREAST 
CANCER 
3.1 INTRODUCTION 
The American Cancer Society estimates 178,480 people will be diagnosed with breast 
cancer in 2007 and 40,460 people will die from breast cancer.[187]  Breast cancer is the second 
leading cancer cause of death among women (lung cancer is first).[188]  Most patients are 
treated by surgery followed by an adjuvant therapy such as radiation, chemotherapy, or 
biological therapy.  An alternative solution to systemic chemotherapy would have a high impact 
clinically. The current study was designed to examine the efficacy of a scaffold to release 
chemotherapy locally and act as a temporary filler to support the contour of the breast following 
lumpectomy. This approach could serve as an alternative to adjuvant breast irradiation. We have 
examined the release of factors from microspheres alone (Chapter 2), in this chapter we examine 
the use of PLGA microspheres in an FDA-approved, natural hydrogel, gelatin.  As such, 
doxorubicin encapsulated microspheres were fabricated and incorporated into gelatin scaffolds 
during gelation.  In vitro release kinetics and efficacy was demonstrated utilizing a murine 
mammary tumor cell line, 4T1.  The ability of the scaffold to eradicate tumor in vivo was also 
assessed.  A lumpectomy model was used by inoculating Balb/c mice with 4T1 cells in the 
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mammary fat pad.  A scaffold was then implanted adjacent to the fat pad.  Mice were sacrificed 
and tumor eradication was analyzed.  The biocompatibility and radiotransparency of the scaffold 
in vivo was also analyzed.  Incorporating the microspheres in the gelatin scaffolds further 
controlled the release of doxorubicin.  The scaffolds effectively eradicated tumor in vitro and in 
vivo, and the scaffold is radiotransparent.  The drug-polymer scaffold can be used as a controlled 
delivery system to potentially eradicate tumors and preserve soft tissue contour. 
3.1.1 Breast cancer and current treatments 
Breast cancer originates from the lining of the milk duct either from duct cells or lobules 
at the ends of the ducts.[189]  Breast cancers are thus categorized as ductal or lobular carcinoma 
or mixed (a combination of both).   Breast cancer can be treated with local treatments to prevent 
cancer from recurring or systemically to destroy cells that have metastasized. Early breast 
cancers may be appropriately treated with a combination of breast conserving surgery along with 
adjuvant breast irradiation.[190] The surgery removes the tumor, which means that some cancer 
cells may remain in the breast.  The role of adjuvant breast irradiation is to reduce the local 
recurrence rate associated with breast conserving surgery alone.[191] Radiation therapy however 
is expensive, time consuming, and increases the cosmetic deformity of surgery.[192] The 
cosmetic deformity resulting from surgery and radiotherapy is synergistic and consists of both a 
volume loss and contour deformity, which is individually variable and can be pronounced 
(Figure 3-1).[193, 194] Surgical correction of the deformed, treated breast is technically difficult 
and involves the transfer of tissue from the surrounding breast or adjacent chest wall using 
plastic surgery techniques.[195, 196] In the absence of surgical repair, the lumpectomy defect 
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fills with fluid and there is a gradual ingrowth of fibrous (scar) tissue and the area contracts. 
There is a limited capacity for the surrounding adipose tissue to regenerate in the defect.  
 
Figure 3-1.  Deformation following surgery and radiation therapy. 
3.1.2 Delivery systems to treat cancer 
Some patients may be treated with systemic chemotherapy either as adjuvant therapy (at 
the time of diagnosis) or to treat cancer that has metastasized to other areas of the body.   Seven 
drugs are commonly used as systemic adjuvant chemotherapy for breast cancer 
cyclophophamide, methotrexate, 5-fluorouracil, doxorubicin, epirubicin, and paclitaxel or 
docetaxel.[189]   Many side effects occur due to systemic treatment, including nausea, vomiting, 
loss of appetite, and hair loss.  Due to these systemic side effects or hard to target tumors, 
polymer/chemotherapy conjugates have been developed for regional therapy.  The treatment of 
brain metastases has been treated in this manner and presumably a similar approach could serve 
as an effective adjuvant treatment for patients undergoing breast conservation surgery for breast 
cancer. Polymeric delivery devices can be utilized to safely delivery chemotherapy locally.  
Figure 3-2 demonstrates the compartmental representation of the transport of drugs from locally 
injected microspheres, demonstrating the pathway of the drug to the blood and healthy tissue.   
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 Figure 3-2 Compartmental representation of the transport of released drugs from polymeric microspheres 
injected intratumorally.[197] 
 
Polymeric delivery devices have been clinically utilized to treat patients. Polymeric 
chemotherapy devices currently available include Zoladex® (AstraZeneca) and Lupron Depot® 
(TAP Pharmaceutical Products Inc.)[198] to treat prostate cancer, Gliadel® (MGI Pharma) to 
treat brain cancer, Sandostatin LAR® Depot (Novartis) to treat acromegaly, carcinoid syndrome 
or VIPoma. One case has been examined for the treatment of breast cancer utilizing regional 
chemotherapy from doxorubicin-loaded albumin microspheres.[199] A Phase II clinical trial 
examined the efficacy of treating metastatic breast cancer with albumin-paclitaxel 
nanoparticles.[200]  By utilizing the nanoparticles a higher dose could be given (300mg/m2) than 
normal (135-200mg/m2) which resulted in a significant anti-tumor effect.  Delivery of 
chemotherapy from polymer microspheres injected along solid tumors results in eradication of 
the tumor compared to little effect when treated with a bolus injection or systemic 
chemotherapy.[201]  Experiments with PLA microspheres in vivo demonstrated that locally 
released doxorubicin could not be detected in systemic serum levels.[202]  
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A slow release biodegradable polymer scaffold could be placed in the breast defect at the 
time of a lumpectomy and would serve two purposes. First, the controlled delivery of a 
therapeutic agent (chemotherapy or biotherapy) to the breast could theoretically control local 
tumor recurrence. Second, the implant would act as a temporary filler, supporting the contour of 
the breast and eventually encouraging tissue ingrowth. The clinical need to both deliver drugs 
locally and support tissue growth into the surgical defect with differing time kinetics suggest the 
design of a biphasic construct. The ideal device should be transparent to the conventional 
imaging modalities used to follow breast cancer patients. This approach could hypothetically 
serve as an alternate to adjuvant breast irradiation resulting in an improved cosmetic result, and 
cost reduction as well as the potential to individualized therapy and improve current outcomes.  
3.1.3 Doxorubicin 
Doxorubicin (Figure 3-3), an anthracycline antibiotic with an antitumor effect, interacts 
with DNA to inhibit cellular functions.[203, 204] Doxorubicin, also known as adriamycin, has a 
molecular weight of 280g/mol.  Doxorubicin has been used to treat cancer for almost four 
decades.  Treatment with doxorubicin is restricted due to its cumulative-dose limit to prevent 
cardiotoxicity.[205-207] Doxorubicin is limited to a lifetime dose of 450-550mg/m2 because of 
cardiotoxicity.[207]  However using a controlled, biodegradable delivery system may reduce the 
distribution of drug in the heart[207] and thus a higher dose may be delivered. In addition, 
doxorubicin is unstable in an aqueous environment at 37oC and pH=7.4.  Fan et al. observed a 
30-40% degradation of doxorubicin over 48 hours; however, when placed in a gelatin implant 
the drug was stable for up to 5 months at these conditions.[208] Due to these limitations, various 
drug delivery systems have been studied, including microspheres,[202, 209-211] 
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pegylation,[212-216] and liposomes[217-219] to deliver doxorubicin. The fabrication technique 
and construct material should be chosen based on the hydrophobicity of the drug, the duration of 
its therapy, and the intended use/implantation site. The delivery of doxorubicin from controlled 
delivery systems has been examined (Table 3-I). 
 
Figure 3-3.  Structure of doxorubicin. 
 
Table 3-I.  Delivery systems of doxorubicin. 
Polymer Microspheres [201, 202, 209, 211, 220] Pegylated Liposomes [212-216] 
Dextran Microspheres [221] PVA Micelles [222] 
Chitosan Microspheres [223] HPMA hydrogel [224, 225] 
Ion Exchange Microspheres [226, 227] Gelatin [208, 228] 
Albumin Microspheres [229] Silica gel [230] 
Polyisohexylcyanocarylate Nanoparticles [231, 232] Starch [233] 
Liposomes [217-219, 234] PCL-Chitosan-PEG [235] 
 
In vivo experiments have demonstrated the anti-tumor efficacy of dextran 
microspheres[221, 236] and PLGA microspheres[201] for the treatment of breast cancers. 
Minimal systemic toxicity as well as prolonged animal survival was seen in groups treated by the 
microspheres. Similarly, Konishi et al. demonstrated the advantages of controlled delivery of 
doxorubicin from gelatin scaffolds.[228] Their results showed a significant decrease in tumor 
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(fibrosarcoma) size as well as an increase in prolonged survival without toxic effects. By 
incorporating doxorubicin into gelatin hydrogels, sufficient intratumor levels were maintained 
over 14 days.  Yoo et al. demonstrated the advantage of a single injection of doxorubicin-loaded 
PLGA nanoparticles over daily injections of free doxorubicin to treat tumors in vivo.[220]  
Similarly, Lin et al. saw an increase in cytotoxicity of doxorubicin delivered from PLGA 
microspheres compared to the free drug.[209]   
3.1.4 Gelatin 
Gelatin is commonly used in both the pharmaceutical and biomedical field.  It is 
nontoxic, biodegradable, inexpensive, nonimmunogenic, and FDA approved. Gelatin was first 
approved by the FDA as a food ingredient and was approved the status of Generally Regarded as 
Safe (GRAS).  In 1993, the FDA reapproved the GRAS status of gelation.  Gelatin is a 
macromolecular protein derived from collagen. Gelfoam, a commercially available sterile gelatin 
is commonly used clinically.  Gelatin has been widely studied for drug and protein delivery, as 
gelatin microspheres[20, 62, 63, 65] or gelatin hydrogels.[55, 140, 208, 228] Gelatin has also 
been examined for use as scaffolds for tissue engineering.[237-239]  In this study we 
encapsulated doxorubicin in PLGA microspheres embedded within gelatin scaffolds to obtain 
local controlled delivery to treat breast cancer. 
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3.2 METHODS 
3.2.1 Doxorubicin encapsulation and characterization 
Doxorubicin (Dox) was encapsulated in PLGA microspheres using a protocol previously 
described by Mallery et al.[210] Dox microspheres were prepared using a double 
emulsion/solvent evaporation method.  250mg of PLGA (75:25) was dissolved in 0.80 mL of a 
mixture of 1:6 methanol to MC.  6mL of 2mg/mL doxorubicin-HCL solution (Bedford 
Laboratories, Bedford OH) was added to the PLGA solution.  The combined solution was 
emulsified by adding 1.0 ml of 1% PVA solution and vortexed for one minute. This emulsion 
was poured into 50 mL of 0.30% PVA and stirred for 2 hours at 550 rpm.  The microspheres 
were collected by centrifugation, washed with DI water, frozen, and freeze-dried.  Empty PLGA 
microspheres were prepared by the same procedure, without the addition of the drug.  The yield, 
loading capacity, and encapsulation efficiency of the microspheres were determined.  The 
microspheres were examined morphologically by SEM.  The images were also used to determine 
the diameter distribution of the Dox microspheres.   
3.2.2 Doxorubicin gelatin constructs 
Gelatin was crosslinked with glutaraldehyde following protocols by Ulubayram et 
al.[240] and Kang et al.[237]  Briefly, to prepare crosslinked gelatin scaffolds, 25 mL of 3% 
gelatin solution (Sigma Aldrich) was prepared.  0.4mL of 0.5% glutaraldehyde solution was 
added and the solution was stirred for an additional 5 minutes.  The solution was then poured 
into a mold and allowed to stand for 12 hours.  The gelatin was treated with 0.1M glycine 
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followed by a water wash to react with any remaining glutaraldehyde.  The gelatin was frozen at 
–20°C.  Scaffolds to be examined by SEM were freeze-dried. To incorporate PLGA 
microspheres into the gelatin, the gelatin was prepared as previously mentioned and the desired 
amount of microspheres were added to the gelatin in the mold and sufficiently mixed.  The 
scaffold was frozen, and samples prepared for SEM were freeze-dried. 
3.2.3 Release of Doxorubicin from microspheres and gelatin constructs 
The release profile of Dox from PLGA microspheres was determined by incubating 
16.5mg of microspheres in 1 mL of PBS (pH 7.4) at 37 °C (n=5). At appropriate intervals, the 
samples were centrifuged and refreshed with 1 mL of PBS. The amount of Dox released into the 
PBS was detected by measuring the absorbance of the supernatant at 483 nm using a Genesys10 
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA). Gelatin cylinders were punched 
out using a 6 mm dermal biopsy punch.  The gelatin cylinder was placed in 1 mL of PBS at 37°C 
(n=5).  The amount of Dox released was also determined spectrophotometrically as described 
above. 
3.2.4 Effects of Doxorubicin on cancer cells in vitro 
The effects of Dox on 4T1 tumor cells (ATCC, murine mammary tumor cell line) were 
determined quantitatively by the addition of various concentrations of Dox to the media.   The 
4T1 mouse mammary tumor cells were maintained in 4T1 media (RPMI 1640, 10% FBS, 1% 
p/s, 2mM L-glutamine, 10mM MEM essential amino acids, 1mM sodium pyruvate) and 
passaged two times a week.   4T1 mouse mammary tumor cells were seeded in a 96-well tissue 
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culture plate at a concentration of 7500 cells per well (n=5). Cells were incubated at 37°C for 24 
hours. Media was replaced with 0.017mg/mL Dox serially diluted 1:1 to 1:16 in media and 
incubated for 24 hours.  Utilizing MTT, the number of viable cells was determined, measuring 
the absorbance at 570 nm (Tecan SpectraFluor).   
 The induction of 4T1 cell death due to Dox was assessed qualitatively using propidium 
iodide to stain the dead cells.  Propidium iodide is a simple qualitative cell viability assay that 
stains non-viable cells red; it cannot cross the membrane of viable cells.  Adherent cells were 
prepared by seeding 4T1 cells on circular 18mm sterile glass coverslips in 12-well polystyrene 
tissue culture plates and cultured until confluent.  Non-adherent cells were removed by washing 
with PBS. The remaining cells were treated with various concentrations of Dox (1mg/mL, 
0.17mg/mL, 0.017mg/mL, 0.0017mg/mL) for 4 hours, 6 hours, and 24 hours. At the end of each 
time point, the medium was removed, followed by a gentle PBS wash. 1mL of PBS with 5μL of 
the 1mg/mL propidium iodide (Sigma) stock solution was added to each well. The cells were 
imaged live with a fluorescent microscope after incubation for 15 minutes at room temperature.   
The activity of the released Dox was examined by determining the induction of cell death 
of the 4T1 tumor cells.  The cells were seeded in a 24-well tissue culture plate with 4T1 media.  
One mL of 10,000 cells/mL media was added to each well and then incubated at 37°C for 12 
hours.  Five treatment groups were examined: 1) 4T1 media, 2) Dox-loaded microspheres, 3) 
Dox-loaded microspheres in gelatin, 4) Empty microspheres and 5) Empty microspheres in 
gelatin (n=5 for each).  The microspheres and gelatin constructs were placed in Transwell® 
baskets.  The amount of microspheres alone and microspheres embedded within the gelatin 
construct were equivalent (34.2mg).  The cells were incubated at 37°C for 48 hours.  The cells 
were then washed with PBS and frozen at –80°C. 
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3.2.5 Scaffold preparation and characterization for in vivo experiments 
The gelatin constructs were prepared as previously described (Section 3.2.2).  For the in 
vivo scaffolds, 129.3mg microspheres per scaffold were added to the gelatin solutions and 
thoroughly mixed.  The gelatin constructs were punched out using a 6mm dermal biopsy punch 
(Figure 3-4).  Constructs that were to be examined by a scanning electron microscope (SEM) 
were freeze-dried. The constructs were examined morphologically by scanning electron 
microscopy (SEM).   
 
Figure 3-4.  Representation of Dox scaffold used for in vivo studies. 
3.2.6 Inoculation of tumor 
An animal model of a lumpectomy was created by inoculating the mice with tumor and 
treating them at the same time point.  4T1 tumor cells were maintained in 4T1 media and 
passaged 2 times a week. 4T1 cells were labeled with CFDA-SE (carboxy-fluorescein diacetate, 
succinimidyl ester) (Molecular Probes) as described by the manufacturer’s protocol.  The 
viability of the cells was examined utilizing trypan blue after labeling and before implantation.  
Cells were then suspended in 4T1 media to a final concentration of 106 cells/mL.  Female 
BALB/c mice were inoculated in the lower left mammary fat pad with 105 4T1 cells in 100 µL of 
4T1 medium at day 0.   
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3.2.7 Implantation of scaffold 
The mice were anesthetized with ketamine and xylazine.  A skin incision was made next 
to the inoculated mammary fat pad.  The constructs were inserted under the skin over the 
mammary fat pad (Figure 3-5).  The incision was closed with sutures followed by VETBONDTM 
tissue adhesive (3M).   
 
Figure 3-5. Implantation of gelatin scaffold.  
 Incision made above mammary fat pad (a) gelatin scaffold slid into place over the mammary fat pad (b). 
3.2.8 Radiography analysis 
The radiotransparency of the constructs was determined by examining X-rays of the mice 
after implantation of the constructs.  Mice were treated (as described above) with one of the 
following: 1) implantation of empty construct and no tumor, or 2) implantation of empty 
construct plus tumor.  After 14 days, the mice were sacrificed and immediately x-rayed.  
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3.2.9 Tumor eradication and side effects 
Directly following inoculation with tumor, the mice were treated with one of the 
following groups:  1) two dox MS gelatin constructs (2Dox) (n=10), 2) one dox MS construct 
(n=5), 3) one empty MS construct (n=10), or 4) nothing (n=10).  The constructs were implanted 
as described above. The mice were initially weighed and then throughout the course of the 
experiment.  Their weight was expressed as a percentage to initial body weight.  The mice were 
sacrificed at day 23.   The tumors were excised and the tumor diameters were measured using 
calipers.  The volume was then calculated using the formula v=ab2, where a and b are 
perpendicular diameters and a > b.[241]  
3.2.10 Optimization of delivery system 
Gelatin solutions, either 3% or 5%, were crosslinked utilizing a glutaraldehyde solution.  
Gelatin scaffolds were punched out using a 6mm dermal biopsy punch.  Scaffolds were placed in 
1mL PBS at 37oC.  PBS was replaced every other day for 150 days, and then the PBS was 
replaced weekly until the end of the study.  Once scaffolds became viscous, instead of solid, they 
were considered degraded. 
A relatively large amount of Dox microspheres was required to successfully treat the 
mice, 2Dox scaffolds.  By encapsulating Dox in the powder form, the encapsulation efficiency 
may increase.  Doxorubicin microspheres were encapsulated as previously described (Section 
3.2.1), except 6mg of powder Dox (Fisher Scientific) was added instead of 6mL of Dox-HCL.  
Doxorubicin powder microspheres (~15mg) were placed in PBS (n=3).  The released 
doxorubicin was measured as previously mentioned (Section 3.2.3) 
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3.2.11 Statistical analysis 
The results are expressed as means ± standard deviations.   Unpaired, two-tailed t-tests 
were performed at each time point.  Comparisons of means representing multiple measurements 
over time were analyzed using repeated-measures analysis of variance (ANOVA) and least 
squares deviation.  The threshold for statistical significance was set at p ≤ 0.05.   
3.3 RESULTS 
3.3.1 Effects of doxorubicin on cancer cells 
The induction of cell death due to Dox was determined using the MTT assay.  As 
expected, the 4T1 cells responded in a dose-dependent manner to the Dox.  As the concentration 
of Dox was increased, the number of viable cells was reduced (Figure 3-6).  A significant 
decrease in viable cells at each concentration of Dox was observed when compared to the control 
(0mg/mL).  After 24 hours, 62,015 ± 3,717 viable cells were present in the control (0mg/mL 
Dox) compared to the lowest concentration of Dox, 37,910 ± 2,902 cells remained viable 
(p<0.0001).  The highest concentration of Dox resulted in 14,935 ± 1,855 viable cells 
(p<0.000001, compared to control). 
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Figure 3-6.  Viable cell number following treatment of 4T1 cells with doxorubicin. 
All values are reported as means ± standard deviations (n=5).  A significant difference (p<0.05) was observed 
between each groups except between 0.0010625 and 0.002125mg/mL dox.[242] 
 
Propidium iodide was used to qualitatively assess the effect of Dox on 4T1 cells. Dead 
cells stained red with propidium iodide.  As seen in Figure 6, as the concentration of Dox 
increased, the number of cells stained red.  This trend corresponds to that of the MTT assay. 
(Figure 3-7) 
 
Figure 3-7.  Stained dead 4T1 cells, using propidium iodide. 
4T1 cells treated with 0.0017mg/mL Dox(a), 0.017mg/mL Dox(b), 0.17mg/mL Dox(c), and 1mg/mL Dox(d) for 
6 hours (200x).[242] 
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3.3.2 Doxorubicin microsphere and gelatin construct characterization 
The Dox PLGA microspheres were characterized using SEM.   The microspheres 
exhibited a smooth round morphology (Figure 3-8).  The diameter of the Dox microspheres was 
determined from SEM images.  The average diameter was 73.55 ± 75.32 μm.  The diameter 
distribution of the microspheres is shown in Figure 3-9. The yield for the Dox-loaded 
microspheres was 61.44 ± 6.81%.  The loading capacity of the dox microspheres was 0.66 ± 0.41 
µg per mg of microspheres.  The encapsulation efficiency was 1.03 ± 0.65%. 
 
Figure 3-8.  SEM of doxorubicin PLGA microspheres. 
Under low magnification (a) and high magnification (b).[242] 
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Figure 3-9.  Diameter distribution of doxorubicin microspheres.[242] 
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 The gelatin constructs were characterized using SEM.  As seen in Figure 3-10, the 
microspheres were embedded within the gelatin pores and appear to be distributed 
homogenously.  The gelatin scaffolds were porous with an average porosity of 46.1 ± 11.1%.  
 
Figure 3-10.  SEM of doxorubicin microspheres embedded in gelatin scaffolds.  
The white arrows point to microspheres.[242] 
 
The release of Dox from the PLGA microspheres and gelatin constructs was examined by 
placing the microspheres or gelatin in a centrifuge tube and measuring the absorbance of the 
supernatant at various time points.  The release of Dox from the microspheres was controlled and 
maintained over 30 days, as shown in Figure 3-11.   The release profile of the Dox microspheres 
was compared to the release from the Dox microspheres embedded within the gelatin construct.  
The release from the gelatin was delayed when compared to the Dox microspheres alone.  
Comparing the percent of total Dox released from the microspheres alone to the gelatin 
constructs, the difference between the release rates can be determined.  On Day 1 the Dox 
microspheres released 10.8 ± 6.0% of their total amount of drug released and the gelatin 
constructs released 7.6 ± 0.5%.  About 50% of the total Dox released was released by the 
microspheres on day 8 (49.0 ± 11.0%) and by day 11 for the gelatin constructs (51.5 ± 2.7%).   
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The microspheres released about 90% ot the total released doxorubicin, 90.3 ± 2.0%, by day 20 
and the gelatin constructs released 91.0 ± 3. 8% by day 26. Over days 5 through 16, the 
cumulative release was statistically significantly higher from the Dox microspheres alone 
(p<0.05).  
 
Figure 3-11.  Percent cumulative release of doxorubicin.   
Release from doxorubicin microspheres (-♦-) and doxorubicin microspheres embedded in gelatin scaffolds (-
■-).  *p<0.05, between PLGA microspheres and PLGA microspheres embedded within gelatin at each time 
point (days 5-16).  All values reported as means ± standard deviations (n=5). 
3.3.3 In vitro effects of microspheres and gelatin constructs on 4T1 cells 
The bioactivity of the released Dox was determined by the effectiveness of Dox to induce 
4T1 cell death.  Four treatments were examined and compared to 4T1 cells cultured in 4T1 
media.  Figure 3-12 depicts the percent viable cells (normalized to 4T1 cells in 4T1 media).  The 
Dox released from both the Dox microspheres and Dox gelatin significantly reduced the number 
of viable cells (p<0.001).  The 4T1 tumor cells treated with the microspheres alone were exposed 
to 0.0051mg/mL of Dox over 48 hours.  There was not a significant difference between the 
released Dox groups.  The effect of empty microspheres was also examined; induction of cell 
death did not occur due to the empty microspheres alone.  Residual glutaraldehyde from 
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crosslinking the gelatin constructs was a concern, thus empty microspheres embedded within 
gelatin was also assessed.  However, no significant induction of death was seen in the 
glutaraldehyde crosslinked gelatin group.   
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Figure 3-12.  Viable cell number normalized to cells in 4T1 media after treatment for 48 hours. 
All values are reported as means ± standard deviations (n=5).  *p<0.05 when comparing dox MS to empty 
MS, empty MS/gelatin, and 0mg/mL dox in media.  #p<0.05 when comparing dox MS/gelatin to empty MS, 
empty MS/gelatin, and 0mg/mL dox in media.[242] 
3.3.4 In vivo scaffold characterization 
 The constructs were examined by SEM. The microspheres are distributed 
homogenously through the porous gelatin constructs (See Figure 3-13). 
 
Figure 3-13.  SEM of microspheres in gelatin scaffolds for in vivo studies. 
Arrows point to doxorubicin microspheres embedded within the scaffold. 
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3.3.5 X-ray/mammography 
Mice with and without tumor were implanted with empty MS constructs.  X-rays were 
performed to determine the radiotransparency of the constructs.  Figure 3-14a, is the x-ray of a 
mouse with a tumor and an empty MS construct. The circle and arrow denote the area of the 
tumor and the construct.   Figure 3-14b, depicts a mouse with only an empty MS construct, no 
tumor.  The arrow denotes the site of the empty MS construct, which cannot be 
detected/observed on this x-ray.  As the tumor can be seen in Figure 3-14a and no construct is 
seen in Figure 3-14b, we conclude that our scaffold is radiotransparent. 
 
Figure 3-14.  X-rays of mice after 7 days.   
Mouse inoculated with tumor and treated with empty MS scaffold (a), circle denotes tumor.  Mouse with 
empty MS scaffold implanted (b), arrow denotes area of scaffold. 
3.3.6 Tumor eradication  
The effectiveness of the constructs to eradicate the tumors was determined by inoculating 
mice with 4T1 tumor cells and treating them with gelatin constructs.  The mice that received no 
treatment, empty constructs, or one Dox construct developed tumors.  The excised tumors were 
measured with calipers (Figure 3-15).  The volume of the tumors from the mice treated with 
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2Dox constructs, dox construct, and empty constructs are shown in Figure 3-16. No tumors were 
observed in the mice treated with 2Dox.  The body weight of the each mouse was measured 
through the experiment to examine the toxicity due to treatment with doxorubicin.  Figure 3-17 
shows the time profile of the body weight following implantation of the constructs.  Over the 23 
days, the body weight of the mice treated with 2Dox constructs decreased.  However, the weight 
loss was <10% of their initial body weight, and thus considered tolerable.   
 
Figure 3-15.  Tumor formation after 23 days in vivo. 
Mouse with tumor treated with no scaffold (a).  Excised tumor from mouse (b). 
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Figure 3-16.  The volume of tumors excised from the mice after 23 days in vivo.  
*p<0.05 compared to mice treated with 2Dox scaffolds.  All values reported as means ± standard deviations. 
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Figure 3-17.  Percent body weight of mice after 23 days of treatment. 
Percent body weight of mice treated with 2Dox scaffolds (-♦-), Dox scaffold (-■-), and empty scaffold (-▲-). 
3.3.7 In vivo degradation of the scaffolds 
Since the scaffolds were not grossly visible after 23 days, the degradation of the scaffolds 
after seven days was examined. Mice were treated with either 2Dox constructs or 2 empty 
constructs.  After seven days, the mice were sacrificed.  The tumor, construct, and surrounding 
area were fixed in 10% buffered formalin and embedded in paraffin.  The slides were stained 
with H&E and Masson’s Trichrome.  After seven days, the scaffolds were present, as seen by 
gross observation (Figure 3-18).  Staining with Masson’s Trichrome demonstrated the presence 
of gelatin (Figure 3-19).  Masson’s Trichrome stains collagen blue, so the remaining gelatin will 
stain blue.    
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a  b 
Figure 3-18.  Scaffolds present after 7 days in vivo. 
Empty MS/scaffold (a), and 2Dox scaffolds (b), arrows point to scaffolds. 
 
 
Figure 3-19.  Masson’s Trichrome staining of scaffold after 7 days in vivo. 
3.3.8 Optimization of the delivery system 
The degradation time of the gelatin scaffolds increased with an increasing glutaraldehyde 
concentration.  Table 3-II shows the degradation time of each scaffold in vitro.  As gelatin and 
glutaraldehyde concentrations were increased, the degradation time also increased. 
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Table 3-II.  Degradation of gelatin scaffolds in vitro. 
Gelatin (w/v 
%) 
Glutaraldehyde 
Concentration 
(mmol) 
Degradation 
time (days) 
3% 0.01 5 
3% 0.02 15 
3% 0.04 >200 
3% 0.08 >200 
5% 0.01 1 
5% 0.02 11 
5% 0.04 >200 
 
By encapsulating doxorubicin in its solid form instead of its liquid form, the 
encapsulation efficiency increased.  The encapsulation efficiency of solid doxorubicin was 14.51 
± 8.90% compared to 1.03 ± 0.65% (liquid doxorubicin).  As the encapsulation efficiency was 
increased, so was the loading capacity; the loading capacity was 3.85 ± 2.36µg Dox per mg of 
microspheres compared to 0.66 ± 0.41µg per mg of microspheres.  However, the release of 
doxorubicin was much lower and could not be detected utilizing the current method.  The 
encapsulation efficiency and release kinetics could possibly be optimized by altering other 
parameters in the microsphere preparation method.  As discussed in the introduction (Chapter 1), 
many parameters affect the release and encapsulation efficiency of polymer microspheres.   
3.4 DISCUSSION 
In our study, we have demonstrated a controlled release of Dox by encapsulation in 
PLGA microspheres that were incorporated into a gelatin construct.  The choice of PLGA for the 
microspheres is based on the widely reported use of FDA-approved PLGA for drug delivery.  
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The encapsulation of Dox into polymer microspheres has been demonstrated.[202, 210, 243] For 
example, Lin et al. reported a 60-70% total release on Day 1 from single-wall 
microparticles.[243] Recently, Tan et al. fabricated double-walled microspheres containing Dox 
in an attempt to further control the drug release.[244]  They reported an initial release of 0.89-
12.89% depending upon the ratio of PLLA to PLGA within the first 6 hours.   In our study at 
Day 1, the microspheres alone released 10.8% ± 6.0% of the total Dox released and the Dox 
released from the gelatin constructs was 7.5% ± 0.5%.   Furthermore, the release of Dox was 
significantly delayed during days 5-16 when the PLGA microspheres were incorporated into the 
gelatin.  
In addition to the utilization of PLGA for the microspheres, we chose gelatin as our 
scaffold material.  Crosslinked gelatin has been used as a delivery system of chemotherapeutic 
drugs.  Fan et al. studied the in vitro release of Dox from glutaraldehyde crosslinked gelatin for 
local delivery.[208] They reported that the non-crosslinked implants were insufficient due to 
poor mechanical strength and a quick release of the drug.  However, glutaraldehyde crosslinked 
implants resulted in a more controlled release. By crosslinking the gelatin, the resistance of the 
scaffold material for diffusion of the drug was increased.  Muvaffak et al. examined the effect of 
glutaraldehyde concentration on the release of the cytotoxic drug, colchicines, from gelatin 
microspheres.[245]  As the amount of glutaraldehyde was increased, a slower release profile of 
the drug occurred.  In our study, we crosslinked gelatin with glutaraldehyde not only to 
sufficiently tailor the release of the Dox, but to also maintain the scaffold strength and thus 
maintain the shape or contour of the breast.  It is possible that Dox may become crosslinked in 
the presence of glutaraldehyde, as stated by Fan et al.[208] To avoid this potential reaction, we 
incorporated the Dox-loaded PLGA microspheres into the gelatin that had already reacted with 
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glutaraldehyde for at least 5 minutes.  Remaining residual glutaraldehyde was reacted with 
glycine, prior to the release of Dox from the microspheres.  Due to our fabrication process, it 
appears as though very little, if any, Dox was crosslinked due to glutaraldehyde.  We propose 
that glutaraldehyde would only be able to react with Dox released into the gelatin solution during 
the fabrication process.  As such, the Dox released from the microspheres during the in vitro 
release studies was not inhibited by crosslinking due to residual glutaraldehyde.  Our results are 
also consistent with those of Konishi et al.[228] They prepared gelatin hydrogels that were 
crosslinked with glutaraldehyde, freeze-dried, and then added a solution containing doxorubicin 
and cisplatin.[228] They did not report an observed interaction between the Dox and the gelatin 
sponge that was already crosslinked with glutaraldehyde.  Furthermore, they did not observe a 
delayed release; approximately 60-80% and 8-20% of Dox and cisplatin, respectively, were 
released within 6 hours. 
Research in the area of microsphere-incorporated scaffolds has focused on both the 
inclusion of native[21, 246-248] and synthetic[18, 76, 249-253] polymeric microspheres within 
scaffolds.  For example, gelatin microspheres incorporated within gelatin scaffolds has been 
studied by Ulubayram et al.[246] Holland et al. examined gelatin microspheres encapsulating 
TGF-β1 in oligo(poly(ethylene glycol) fumarate) (OPF) hydrogels.[20, 21]  Their study resulted 
in a more controlled release when the microspheres were incorporated in the OPF gel. Although 
microspheres containing drugs, proteins, or growth factors have been incorporated post-
fabrication,[254] the inclusion of polymer microspheres during fabrication has been less studied.  
Zhang et al. assessed the release from hydroxyl-functionalized glycerol poly(ε-caprolactone) in 
poly(n-isopropylacrylamide) (PNIPAAm) hydrogels.[249]  They also reported a more controlled 
release from the microspheres incorporated into PNIPAAm.  Elisseeff et al. reported the 
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controlled release of IGF-I and TGF-1 from PLGA microspheres incorporated in PEO-based 
hydrogels.[18]  Our lab has reported the incorporation of PLGA microspheres within PLGA 
scaffolds,[250, 251] fibrin scaffolds,[252] and more recently PEG-based hydrogels.[253] To the 
best of our knowledge we are the first to incorporate PLGA microspheres within gelatin 
scaffolds. A study by Liu et al. following our publication incorporated paclitaxel-PLGA 
microspheres in gelatin scaffolds.[255] The release was not different from the microspheres in 
the gelatin sponges compared to the microspheres alone.  However, this is most likely due to the 
non-crosslinked gelatin as they state crosslinking the gelatin may further limit the release. 
In the present work, we demonstrated the ability to induce cell death by doxorubicin 
delivered from the gelatin constructs in vitro.  Lin et al explored the cytotoxicity of PLGA 
microparticles with glioma cells in vitro.  They demonstrated a higher toxicity from the 
microparticles compared to free Dox.[243]  In our results, induction of cell death was statistically 
significant in both the Dox microspheres and the Dox gelatin in vitro when compared to no 
treatment, gelatin, and empty microsphere-gelatin treatments (p<0.001).  Our results 
demonstrated a dose-dependent response of the tumor cells to doxorubicin.  Liu et al. 
demonstrated a similar response of hepatoma cells from 0.3µg/mL to 2.5µg/mL of released 
doxorubicin from human serum albumin microspheres.[256]  
The in vitro characteristics of the scaffold suggest potential clinical utility for the 
treatment of patients having not only breast cancer but a variety of other malignancies where 
failure of surgical therapy alone mandates the need for additional therapy (multimodality 
treatment).  We have tested the in vivo properties of the device and the device is capable of 
tumor eradication, biocompatible, and radiotransparent. The scaffolds were implanted into mice 
at the time of inoculation of a mammary tumor.  This model adequately represents the clinical 
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scenario in which the scaffold would be implanted at the time of lumpectomy.  Any remaining 
cancer cells after lumpectomy should be killed by the localized release of Dox from the 
construct, while the defect is filled by the gelatin scaffold.  After the Dox is completely released, 
normal tissue is hypothesized to infiltrate the gelatin scaffold and form healthy tissue.  In this 
study we examined whether a high dose of released Dox at the site would eradicate tumors.   
Emerich et al. examined the effects of the placement of delivery systems.[201].  Their 
results show that placement around the perimeter of the tumor was better than an intra-tumor 
injection.  As such, in this study, we placed the gelatin construct right next to the inoculation site.  
The dose of doxorubicin that would be used to treat these mice based on weight is 0.4µg, in this 
study the mice were treated with a cumulative release of 24 µg over the total 23 days.  Local 
toxicity surrounding the scaffold was not seen in any of the mice.  The mice received no 
treatment, empty scaffolds, Dox scaffold, or 2Dox scaffolds.  The volume of the tumors from the 
mice treated with 2Dox scaffolds indicated complete eradication of the tumors.  Conversely, 
tumors formed in the mice that received no treatment, empty scaffold, or Dox scaffold.  The 
body weight of each mouse was measured through the experiment to examine the toxicity due to 
treatment with such a large dose of doxorubicin, and while the weight of mice treated with 2Dox 
scaffolds decreased, it was considered tolerable.   
The degradation of gelatin scaffolds has been readily examined.  Non-crosslinked gelatin 
sponges were placed in rats in the peritoneal cavity and had partially degraded at 3 days and 
almost complete degradation occurred at 7 days.[255] Ulubayram et al. examined the in vitro 
degradation and cytotoxicity of gelatin scaffolds crosslinked with glutaraldehyde.[239]  Gelatin 
scaffolds crosslinked at a glutaraldehyde of 0.25mmol and 0.5mmol degraded 24 days and 28 
days respectively in vitro.  The scaffolds of 0.25mmol glutaraldehyde were nontoxic whereas the 
 82 
scaffolds with 0.5mmol glutaraldehyde were moderately cytotoxic.  In this study we utilized 
gelatin scaffolds that were crosslinked with a concentration of 0.2mmol glutaraldehyde.  We did 
not see toxicity of the 4T1 tumor cells from the gelatin scaffolds.  The degradation of the 
scaffolds in vivo usually occurs more quickly than in vitro.  Thus as Ulubayram saw degradation 
at 24 days in vitro, we would expect to see degradation at 23 days in vivo. 
We successfully eradicated tumor cells in vitro and in vivo with the Dox scaffold.  
However, further studies involving long term in vivo use to assess tissue ingrowth, a gelatin 
scaffold that degrades more slowly is necessary.  As well, if the encapsulation efficiency of 
doxorubicin can be increased, a smaller amount of microspheres could be embedded within the 
scaffolds.  As such, different concentrations of glutaraldehyde were used to crosslink different 
concentrations of gelatin, and the degradation time in vitro was observed.  We can prepare 
gelatin scaffolds that did not degrade as quickly.  Doxorubicin in its solid form was encapsulated 
in PLGA microspheres and the encapsulation efficiency compared to encapsulation of 
doxorubicin-HCL.  The encapsulation efficiency was increased; however, the release could not 
be determined from the microspheres. 
The observation that 80-90% of local recurrences that occur after surgery and radiation 
occur in the tumor resection bed suggest that the problem is a very local one and questions the 
need for whole breast irradiation.[257] The second relevant observation is that systemic 
administration of chemotherapy reduces the rate of local recurrence. [258, 259] These two 
observations together suggest the testable hypothesis that an implantable chemotherapy delivery 
system can reduce the local recurrence rate associated with surgery alone.  Although direct 
administration of an anticancer agent into tumors of the breast is not routinely performed 
clinically this approach is used to treat other malignancies especially tumors of cutaneous origin 
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again suggesting clinical potential.[260] Clearly much additional preclinical study is necessary 
and this in turn would need to be followed by the design and completion of appropriate 
randomized clinical trials before this modality could challenge the current standard of care.  
Nonetheless there exists an unmet need to improve the current therapy for not only breast cancer 
but other malignancies as well.  
3.5 CONCLUSIONS 
In this study we aimed to develop a novel delivery system to locally deliver a 
chemotherapeutic agent as well as maintain the contour of the breast following a lumpectomy.  
We have prepared a controlled delivery system of doxorubicin to maintain local levels of the 
drug. The release was controlled by the incorporation of PLGA microspheres into gelatin 
constructs. The released doxorubicin from both the microspheres alone and microspheres 
incorporated into gelatin demonstrated a cytotoxic effect on 4T1 tumor cells in vitro.  
Implantation of 2Dox scaffolds resulted in tumor eradication in vivo.  A dose 60 times the 
currently recommended dose was given to the mice; however, no adverse reactions were 
observed due to treatment with the Dox scaffolds, the body weight of the mice was not 
drastically effected nor was local toxicity observed.   
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3.6 FUTURE DIRECTIONS 
We successfully achieved our aim of developing a novel delivery system to locally 
deliver chemotherapy and fill in the defect following a lumpectomy.  Future studies must be 
performed to further develop and optimize this system.  We encapsulated doxorubicin-HCL in 
PLGA microspheres; doxorubicin is also available in powder form.  Encapsulation of the powder 
form resulted in a higher encapsulation efficiency.  Similar studies as mentioned above should be 
performed to determine the efficacy of these microspheres to be utilized in this system.   
We utilized gelatin as the scaffold in which to incorporate the microspheres.  In this study 
we examined a low crosslinked gelatin scaffold.  However after 23 days in vivo, we could not 
detect the scaffolds by gross observation.  Our aim was to have a scaffold that would slowly 
degrade and allow tissue ingrowth.  Therefore, a scaffold that degrades more slowly would be 
optimal.  We have examined the degradation in vitro of gelatin scaffolds of various 
glutaraldehyde and gelatin concentrations.  As such the scaffold of 3% gelatin and 0.4 ml of 
1.0% glutaraldehyde (0.04mmol) is recommended for further examination.  An injectable 
hydrogel that would gel in situ to fill any size and shape defect should also be examined.  We are 
currently developing a novel PEG hydrogel that may be utilized for this application (See Chapter 
5).   
Furthermore, Konishi et al. demonstrated an increased effect by releasing both 
doxorubicin and cisplatin.[228]  We have done some experiments to encapsulate cisplatin in 
PLGA microspheres (See Appendix B).  In our delivery system, we could easily incorporate 
cisplatin-loaded PLGA microspheres in the gelatin scaffold in addition to the doxorubicin-loaded 
PLGA microspheres. 
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Finally, additional control groups could further demonstrate the efficacy of the delivery 
system.  Systemic delivery of dox could be given as a control for tumor ablation as well as 
systemic toxicity.  The systemic levels of dox should be measured to ensure a local delivery from 
the gelatin scaffold. 
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4.0  THE CONTROLLED RELEASE OF TGF-Β1 FROM PEG-GENIPIN 
BIODEGRADABLE HYDROGELS FOR CARTILAGE REPAIR 
4.1 INTRODUCTION 
The need for tissue-engineered cartilage is of immense clinical significance. Traumatic 
and degenerative lesions of articular cartilage are leading causes of disability.[261] The poor 
intrinsic healing potential of articular cartilage is well described.[262] Untreated cartilage 
injuries are thought to progress to degenerative arthritis in the majority of patients.[263] It is 
estimated that over 40 million Americans currently suffer from osteoarthritis.[264] Tissue 
engineering methods to improve cartilage repair and regeneration will therefore have high 
clinical impact. There are two general approaches to tissue engineering of articular cartilage. The 
first approach is that of ex vivo tissue regeneration in which functional cartilage is created in the 
laboratory. Strategies used in this approach include encapsulation of repair cells into scaffolds 
for culture within sophisticated bioreactors delivering growth factors, nutrients, and mechanical 
forces. The second approach to cartilage regeneration focuses on enhancing intrinsic repair 
processes. As such, the emphasis is on augmenting and modulating the in vivo response to injury 
through the addition of scaffolds, cells, and growth factors.   
We have incorporated PLGA microspheres in a naturally derived hydrogel (Chapter 3); 
however, the goal of this chapter is to examine the release from PLGA microspheres within a 
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novel synthetic hydrogel, PEG-genipin.  We have prepared a delivery system to enhance 
cartilage repair.  Transforming growth factor–beta1 (TGF-β1) was encapsulated in PLGA 
microspheres.  The microspheres were incorporated into synthetic hydrogels, PEG-genipin.  The 
release kinetics from the microspheres and hydrogels were determined.  The bioactivity of the 
released TGF-β1 was also evaluated.  The burst release of TGF-β1 was decreased by 
incorporating the microspheres in the hydrogels.  The amount of TGF-β1 released can be tailored 
by the concentration of the crosslinker, genipin, and the amount of microspheres incorporated 
into the scaffolds.   
4.1.1 Cartilage 
Cartilage is a complex tissue that provides shape and support.  Three types of cartilage 
are present in the body: hyaline, elastic, and fibrocartilage.  The cartilage-resident cells, 
chondrocytes, secrete an avascular extracellular matrix.  The extracellular matrix consists of type 
II collagen that provides strength and proteoglycans, which are hydrophilic.[265]  Thus, cartilage 
is biphasic with a solid matrix consisting of a dense collagen network and a gel composed of 
proteoglycans.[266]  Articular cartilage is hyaline cartilage that covers the joint surface where 
one bone meets another which enables a joint to move easily by reducing friction.[267] 
Chondrocytes grown in monolayer dedifferentiate into fibroblast-like cells;[266, 268] 
however, a three-dimensional environment allows chondrocytes to maintain their phenotype and 
redifferentiate.[266] Fresh chondrocytes have a round polygonal morphology. Once they have 
de-differentiated, chondrocytes have a fibroblast morphology.[268]  Thus for cartilage tissue 
engineering, the environment provided is important to maintain healthy cells and tissue.   
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4.1.2 Therapies for cartilage repair 
Traumatic and degenerative lesions of articular cartilage are leading causes of disability.  
Since cartilage is avascular, repair is insufficient.  Current treatments for cartilage repair are 
limited.  Arthroplasty, replacement of the joint with an artificial prosthesis, is one treatment 
option for severe osteoarthritis.   An osteochondral autograft is another option.  In this procedure, 
a small graft is removed from an area that does not bear a lot of weight and is transplanted to the 
damaged area.   Carticel® is the only marketed FDA approved autologous cell therapy.  
Carticel® utilizes autologous chondrocytes by taking a biopsy and expanding the cells de novo, 
which are then implanted.  Another option is to stimulate the marrow by drilling a hole through 
to the bone marrow.  This procedure attempts to stimulate the body to repair itself by having 
repair cells (possibly adult stem cells) from within the blood or bone marrow fill in the defect.  
Recently, tissue engineering with autologous adult stem cells has become a reality for use as a 
therapy.  Wakitani et al. demonstrated the use of autologous bone marrow mesenchymal stem 
cells (BMSCs) to heal articular cartilage defects in humans.[269]  BMSCs were encapsulated in 
collagen gels, the results showed the defects were filled with fibrocartilage and clinical 
symptoms had drastically improved.[270]  The potential for BMSCs to differentiate into 
chondrocytes and repair cartilage defects has been well studied[41, 271-274] and chondrogenesis 
of BMSCs from osteoarthritic patients has also been demonstrated in vitro.[275] 
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4.1.3 Transforming growth factor-β1 (TGF- β1) 
Transforming growth factor-beta1 (TGF-β1) is a 25 kDa protein from the TGF-β super 
family. TGF-β1 acts as a growth inhibitor for epithelial, endothelial and hematopoietic cell 
lineages; however TGF-β1 is stimulatory for cells of mesenchymal origin.[265] TGF-β1 
increases chondrocyte,[276] osteoblast precursor cell,[277] and BMSC[278] proliferation. TGF-
β1 is chemotactic, inducing mesenchymal stem cell recruitment.[279, 280] 
TGF-β1 is an isoform of TGF-β that plays an important role in the growth and 
differentiation of articular cartilage. TGF-β is very abundant in articular cartilage and TGF-β1 is 
the predominant isoform.[281] TGF-β1 has the potential to improve cartilage repair by 
promoting chondrogenic differentiation.[282-288] TGF-β1 promotes chondrogenic 
differentiation in chondroblasts,[282, 283, 285] and in mesenchymal cells such as bone marrow 
stromal cells, perichondrium and periosteum.[284, 286-289] TGF-β1 has been shown to induce 
chondrogenesis,[280, 290] increase collagen type II expression,[276, 280, 291] and GAG 
content.[291, 292]  TGF-β1 also induces bone formation.[277, 278, 280, 293, 294]  A repeated 
administration of TGF-β1 has a superior effect to single application in wound healing and 
sustained release of TGF-β1 induced chondrogenesis of human bone marrow stromal cells.[295, 
296]  In this study we have chosen to examine the sustained release of TGF-β1 from PLGA 
microspheres. 
Sustained TGF-β1 administration is readily accomplished in vitro but poses difficult 
challenges when translated to the in vivo environment. Many investigators have examined the 
controlled delivery of TGF-β1, as seen in Table 4-I. TGF-β1 has been encapsulated in PLGA 
microspheres,[294, 297] PLGA microspheres within hydrogels,[18, 20] chitosan microspheres in 
collagen/chitosan/glycosaminoglycan scaffolds,[291] and gelatin microspheres in PEG-fumarate 
 90 
hydrogels.[21, 22]  In this study, we encapsulated TGF-β1 in PLGA microspheres, which were 
then encapsulated in PEG hydrogels.  
Table 4-I.  TGF-β1 Delivery Systems. 
Polymer Microspheres[278, 294, 297] PLA [298, 299] 
Sodium alginate microspheres[300] Coral Particles[301] 
Chitosan microspheres[276, 277, 291] Liposomes[302] 
Gelatin microspheres in OPF[20-22, 247] Fibrin glue[280] 
PLGA Microspheres in PEO hydrogels[18] PLGA[293] 
Oligo(poly(ethylene glycol) fumarate (OPF)[21, 22] CaSO4[293] 
Gelatin/Gelatin Microspheres[54, 290, 303] Dextran Hydrogels[304] 
Ethylene acetate copolymers[305] Poly(ether-ester)[292] 
Hydroxyapatite[306]  
4.1.4 Scaffolds for cartilage tissue engineering 
Cartilage-like tissue has been grown in numerous scaffolds, including synthetic and 
native.  Collagen is the most extensively studied natural scaffold for cartilage tissue engineering. 
[274, 307-311] Other natural scaffolds investigated include hyaluronic acid,[309, 312-314] 
gelatin scaffolds,[273] fibrin glue,[101, 102, 315] chitosan,[316-318] and alginate.[311, 314, 
319]  Synthetic polymers can be more versatile and modified to obtain desired properties.  
Synthetic polymers such as PCL,[280, 320] PGA,[275, 321, 322] PEG hydrogels,[323-326] 
PEG/PCL hydrogel,[327] polyurethanes,[328], poly(propylene fumarate) (PPF),[309] and 
oligo(poly(ethylene glycol) fumarate) (OPF) [20-22] have been studied as scaffolds for cartilage. 
We are utilizing PEG-based hydrogels as our scaffold material. While synthetic hydrogels are 
commonly nondegradable, biodegradable PEG hydrogels can be obtained via copolymerization 
with degradable polymers such as PLA, PGA and PPF. [16, 21, 329] An objective of this thesis 
is to examine the potential of genipin, a naturally derived molecule, as a crosslinking agent for 
synthetic, biocompatible polymers.  Our laboratory has examined the synthesis of biodegradable 
PEG hydrogels using genipin, a non-toxic crosslinking agent.[25] Genipin is a readily 
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obtainable, naturally-derived compound found in the gardenia fruit and has been utilized as a 
crosslinking agent for primary amines. Genipin has been used to crosslink functional amine 
groups present in natural tissues and native polymers with very minimal cytotoxic effects as 
compared to studies performed with the crosslinking agent glutaraldehyde. [330-332]  Genipin is 
further discussed in Chapter 5.  We have also demonstrated the ability to tailor in vivo 
dissolution of the PEG-genipin hydrogels in osteochondral defects (Appendix C). 
4.1.5 Incorporation of microspheres in scaffolds 
A number of researchers have studied the combination of microspheres and scaffolds for 
controlled drug delivery, including our own laboratory.[20, 21, 333, 334] For example, the use of 
crosslinked polymers can provide highly reproducible delivery of growth factors. Holland et al. 
[20] reported the controlled release of TGF-β1 from crosslinked gelatin microspheres 
incorporated in PEG-fumarate hydrogels. They reported that composites encapsulating less 
crosslinked microparticles exhibited 100% release after only 18 days and were completely 
degraded by day 24 in collagenase-containing phosphate-buffered saline. Hydrogels 
encapsulating higher crosslinked gelatin microparticles did not exhibit 100% release or polymer 
loss until day 28. Their studies confirm that TGF-β1 release and biomaterial degradation can be 
controlled by altering parameters of in situ crosslinkable hydrogels such as PEG[20].  In this 
study, we have incorporated TGF-β1-loaded PLGA microspheres in PEG-genipin hydrogels with 
different crosslinking densities to further control the release of TGF-β1.  
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4.2 METHODS 
4.2.1 Preparation of poly(ethylene glycol) (PEG)-genipin scaffolds 
PEG-genipin hydrogels were prepared by crosslinking poly(ethylene glycol) diamine 
(PEG diamine) with genipin (Figure 4-1).  A 10% (w/v) aqueous PEG-diamine solution was 
prepared by dissolving PEG-diamine in filtered Nanopure water.  An 88 mM genipin aqueous 
solution was added to the 10% PEG aqueous solution, yielding a final concentration of 17.6 mM 
(“PEG-genipin low”) or 35.2 mM (“PEG-genipin high”) genipin.  The solution reacted overnight 
in sealed vials at room temperature.  Once the solutions became dark blue, the crosslinked 
solutions were poured into a Teflon® mold.  After 24 hours, samples were removed and sterilized 
using UV light. 
 
Figure 4-1.  Structure of PEG-diamine (a) and genipin (b).[335] 
4.2.2 TGF-β1 encapsulation and characterization 
TGF-β1 was encapsulated into PLGA microspheres using a double emulsion technique, 
using a protocol previously described.[297]  Briefly, 250mg PLGA (50:50, Sigma Aldrich) was 
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dissolved in 2 mL of MC. Next, 100 µL of a 10 µg/mL solution of TGF-β1 was added to 1 mL of 
a 1% PVA solution, and the solutions were combined. The entire mixture was emulsified on a 
vortexer for 1 min. The solution was re-emulsified in 50 mL of 0.1% aqueous PVA solution, 
resulting in a double emulsion. Next, 100 mL of a 2% aqueous isopropanol solution was added to 
the second emulsion and stirred for 2 hours. The microspheres were collected by centrifugation, 
lyophilized to dryness, and stored at -20°C.  The microspheres were examined morphologically 
by SEM.    
4.2.3 Incorporation of TGF-β1 microspheres in PEG-genipin scaffolds  
PLGA microspheres were weighed and then added to the hydrogel solution in the Teflon 
mold during the final hours of gelation.  Microsphere incorporated hydrogels were characterized 
using SEM.    The mass of incorporated microspheres was equivalent for both the high genipin 
concentration and low genipin concentration. 
4.2.4 In vitro release 
The in vitro release of TGF-β1 from the delivery system was analyzed for the three 
groups.  Analysis of the release kinetics from the TGF-β1 loaded microspheres, TGF-β1 loaded 
microspheres incorporated in “PEG-genipin high” hydrogels, and TGF-β1 loaded microspheres 
incorporated in “PEG-genipin low” hydrogels was conducted using a commercially available 
Enzyme Linked Immunosorbent Assay (ELISA) kit.  To determine the release from the 
microspheres, 10mg of microspheres were placed in a microcentrifuge tube containing 1 mL of 
PBS, pH = 7.4.  The release of TGF-β1 from the microspheres in the PEG-genipin scaffolds was 
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also determined.  The scaffolds were placed in 0.5 mL of PBS in a microcentrifuge tube.  All 
samples were maintained at 37oC up to 21 days (n=5).  At each time point (days 1, 3, 7, 10, 14, 
17, and 21), the tubes were centrifuged and the supernatant collected for analysis.  The samples 
were refreshed with new PBS and then vortexed for 5 seconds.  Percent cumulative release was 
determined by normalizing the cumulative release of TGF-β1 at each time point with the total 
cumulative release of TGF-β1 over the course of 21 days. 
The degradation of the PLGA microspheres was analyzed under the same conditions as the 
release studies described above.  After 14 and 21 days, the microspheres were collected for 
analysis.  The microspheres were then examined by SEM. 
4.2.5 Bioactivity of released TGF-β1 
Activity of TGF-β1 released from PLGA microspheres was measured using the well-
established mink lung cell growth inhibition bioassay.[292, 336, 337]  TGF-β1 loaded PLGA 
microspheres (10mg), empty PLGA microspheres (10mg), TGF-β1-loaded microspheres in PEG-
genipin (high and low), and empty microspheres in PEG-genipin (high and low) were placed in 
250 μL MEM media and kept at 37oC.  At each time point (Day 1, 3, 7, 10, 14, 17, and 21) the 
samples were centrifuged and the supernatant collected.  The samples were refreshed with 250 
μL MEM and vortexed.  Mink lung cells (ATCC, CCL-64) were seeded into 96-well plates at 
5x103 cells per well in MEM with 10% FBS.  After cell attachment, microsphere elutes from 
various groups were added to the wells in triplicate and the cultures were incubated for 48 hours. 
Each assay plate contained control wells with known amounts of TGF-β1, ranging from 1 ng/mL 
to 0.04ng/mL.   Following the incubation period, the media was removed and cells were rinsed 
with PBS and the assay plates were frozen at -70oC.  DNA content of the cells was determined 
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by adding lysing buffer containing 0.1 mM potassium phosphate, pH 7.8, 0.2% Triton x-100, 
1mM dithiothreitol and a 400-fold dilution of PicoGreen dsDNA dye.  Fluorescence was read on 
a SpectraFluor plate reader (Tecan) and TGF-β1 bioactivity was determined by comparing the 
DNA/PicoGreen fluorescence in each assay well with that of cells treated with TGF-β1 standards 
on each assay plate. 
4.2.6 Statistical analysis 
The results are expressed as means ± standard deviations. Unpaired, two-tailed t-tests 
were performed at each time point.  The threshold for statistical significance was set at p<0.05.  
4.3 RESULTS 
4.3.1 TGF-β1 microsphere and PEG-genipin scaffold characterization 
The TGF-β1 loaded PLGA microspheres were prepared using a double emulsion 
technique and then examined using SEM.  The average microsphere size was 86.64 ± 76.88 
microns (Figure 4-3).  The microspheres were spherical and exhibited a smooth surface 
morphology (Figure 4-2 a-b).  Significant morphological changes occurred during the 21 days.  
The surface of the microspheres became rougher and the shape became less spherical.  
Micropores became more evident after 14 days (Figure 4-2 c-d).  At day 21, the microspheres 
began to demonstrate a loss of preservation of their spherical structure (Figure 4-2 e-f).   
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 Figure 4-2.  SEM of TGF-β1 PLGA microspheres.   
TGF-β1-loaded microspheres at Day 0 at high magnification(a) and low magnification(b); after 14 days at 
high magnification(c) and low magnification(d); and after 21 days at high magnification(e) and low 
magnification(f).[335] 
 
 
Figure 4-3.  Diameter distribution of TGF-β1 microspheres.[335] 
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 The microspheres were added to the hydrogel at both concentrations of genipin, 17.6 mM 
and 35.2 mM.  Figure 4-4 depicts the scanning electron micrographs of the microspheres 
embedded in the PEG-genipin gels.   
 
Figure 4-4.  SEM of TGF-β1 loaded microspheres in PEG-genipin hydrogels. 
Microspheres in PEG-genipin low(a) and PEG-genipin high (b).[335] 
4.3.2 Release kinetics from microspheres and scaffolds 
The in vitro release of TGF-β1 from the PLGA microspheres, the TGF-β1-loaded PLGA 
microspheres in PEG-genipin high, and the microspheres in PEG-genipin low into PBS (pH=7.4) 
was determined using an ELISA kit.  The releasate was analyzed at 1, 3, 7, 10, 14, 17, and 21 
days.  The release of TGF-β1 was affected by incorporation into the scaffold as well as the 
genipin concentration of the hydrogel (Figure 4-5).  Within 1 day, the microspheres 
demonstrated a high burst release (69.01 ± 29.25%).  The burst release was delayed in both of 
the hydrogels incorporating the microspheres.  The PEG-genipin high scaffold exhibited a burst 
release on day 3. The majority of the TGF-β1 was released by day 14.  The PEG-genipin low 
scaffolds did not exhibit a large burst, at day 17, 72.7 ± 11.7% of the total released TGF-β1 was 
released.  Statistical analysis of the cumulative release provides further evidence that the release 
is affected by the incorporation into PEG-genipin.  The percent cumulative release of TGF-β1 
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from the microspheres was statistically higher than the release from the PEG-genipin low 
scaffolds with TGF-β1-loaded microspheres at every time point.  Comparing the TGF-β1 loaded 
microspheres to the PEG-genipin high scaffolds with TGF-β1 loaded microspheres, the percent 
cumulative release was only statistically higher at day 1.  The PEG-genipin high scaffold 
exhibited a statistically higher cumulative release of TGF-β1 than the PEG-genipin low scaffolds 
at days 7 and 10.  This evidence demonstrates that incorporating the microspheres into PEG-
genipin scaffolds delays the burst effect commonly seen in the release of growth factors from 
microspheres alone. 
 
Figure 4-5.  Percent cumulative release of TGF-β1. 
Release from TGF-β1-loaded microspheres (-♦-), TGF-β1-loaded microspheres in PEG-genipin high(-■-), 
and TGF-β1 loaded microspheres in PEG-genipin low(-▲-).[335] 
4.3.3 Bioactivity of released TGF-β1 
The mink lung cell growth inhibition assay was used to assess the bioactivity of the 
released TGF-β1.  Table 1 depicts the percent of cell growth inhibition of the mink lung cells 
when exposed to the releasate media from the microspheres when compared to normal growth 
media.  Cell growth was significantly inhibited up to 14 days after release in vitro.  We also 
examined the releasate from the low and high PEG-genipin scaffolds, and cell growth was also 
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initially inhibited (Figure 4-6), indicating that the delivery system fabrication process does not 
affect the bioactivity of TGF-β1. 
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Figure 4-6.  Bioactivity of released TGF-β1.   
Percent mink lung inhibition from TGF-β1 loaded microspheres (-●-), TGF-β1 loaded microspheres in PEG-
genipin high (-▲-), and TGF-β1-loaded microspheres in PEG-genipin low (-□-).  Standard curve for TGF-β1 
inhibition. 
4.4 DISCUSSION 
 
We examined PEG-genipin hydrogels as growth factor delivery vehicles for tissue 
engineering applications. We encapsulated TGF-β1 PLGA microspheres, and subsequently 
incorporated the microspheres into biodegradable PEG-genipin hydrogels. We have determined 
the release kinetics and bioactivity of TGF-β1 from the microspheres, and the microsphere-
loaded hydrogels. The implications of such a controlled release system for understanding the 
effects of growth factors such as TGF-β1 on cartilage repair in vivo is of immense clinical 
significance. 
 100 
In this study, we have demonstrated a significant difference in the release kinetics of 
TGF-β1 from our delivery systems. As expected, TGF-β1-loaded PLGA microspheres 
demonstrated a high burst release, whereas the hydrogels containing the microspheres 
demonstrated a delayed burst release. Interestingly, the PEG-genipin low hydrogel showed a 
longer delay in the release when compared to PEG-genipin high (Figure 4-5). This may be due to 
the faster dissolution of the lower genipin concentration hydrogel, resulting in hydrated PEG 
chains in the gel. We have previously shown that PEG-genipin hydrogels undergo dissolution in 
an aqueous environment, and the PEG-genipin chains are released into the solution.[25]  Each 
leasate solution was blue; however, the PEG-genipin low solution was darker blue, and remained 
blue for a longer period of time as compared to PEG-genipin high. We hypothesize that the delay 
in the release of TGF-β1 from PEG-genipin low may be due to hydrated PEG chains in the 
hydrogel blocking the release of the large TGF-β1 molecule. This hypothesis is supported by 
results of a study conducted by Bajpai et al. who reported the release of insulin from hydrogels 
composed of PVA, PEG, and crosslinked polyacrylimide.[338] In that study, an increase in PEG 
content led to an initial increase in the release of insulin. However, at high levels of PEG, a 
decrease in release occurred. This decrease due to the number of hydrated PEG chains became so 
large that the release of insulin from inside the network was inhibited.  Holland et al. examined 
the release from gelatin microspheres within OPF hydrogels.  They saw similar results to our 
study, in which the release in looser gels was less than that from higher crosslinked gels.[20]  
They claim this may be due to the presence of uncrosslinked entangled polymer chains.  We also 
saw a reduced release in the lower crosslinked hydrogels, which may be due to uncrosslinked 
PEG chains.  
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In this study the release of TGF-β1 was further controlled by incorporating the 
microspheres in either of the hydrogels.  Ganguly et al. saw similar results, in which the release 
of dexamethasone was further sustained by incorporating ethylcellulose microspheres within 
chitosan gels.[137]  Holland et al. also examined the release of TGF-β1 from microspheres 
within a hydrogel.  By incorporating gelatin microspheres within OPF hydrogels, the burst was 
reduced.  More specifically, the release of TGF-β1 was affected by diffusion through the OPF 
hydrogel.[20]  Some investigators have incorporated microspheres within hydrogels, but only 
examined the release from the microspheres alone. Lee et al. examined a 
collagen/chitosan/glycosaminoglycan scaffold incorporating TGF-β1-loaded chitosan 
microspheres.  The release kinetics in vitro were assessed from the chitosan microspheres alone; 
however, they state by incorporating the microspheres within the scaffold further controlled 
release was obtained.[291]  Similarly Elisseef et al. incorporated microspheres in hydrogels and 
only examined the release kinetics from the microspheres alone.[18] 
We also examined the bioactivity of the released TGF-β1 by assessing the inhibition of 
proliferation of mink lung epithelial cells. TGF-β1 is known to be a strong inhibitor of epithelial 
cell growth. For example, Parker et al. determined the bioactivity of released TGF-β3 from 
microtextured silicone and poly-L-lactic acid.[337] They reported that the released growth factor 
partially maintained its bioactivity, with 30–50% of the released growth factor active. In our 
study, we evaluated inhibition of cell growth by exposing mink lung cells to media from the in 
vitro release studies. Figure 4-6 demonstrates the inhibition of cell growth up to 21 days after 
exposure to TGF-β1 released from the PLGA microspheres, and the TGF-β1-loaded 
microspheres incorporated within PEG-genipin high and PEG-genipin low scaffolds. Cell growth 
inhibition was observed when the cells were exposed to media from the microsphere and 
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hydrogel delivery systems, with a significant decrease in inhibition observed at day 1 between 
the two hydrogel scaffolds (p<0.01). At day 1, growth inhibition was 59% for the PEG-genipin 
high scaffold, but only 20% for the PEG genipin low scaffold. By day 3, the difference in cell 
inhibition between the two hydrogels was no longer significant. We observed a decrease in the 
activity of TGF-β1 from the microspheres and from PEG-genipin hydrogels after 7 days, then a 
slight increase in activity after 10 days, which corresponds to the TGF-β1 release profile 
obtained from our ELISA data (Figure 4-5).. The initial loss of TGF-β1 activity may be 
attributed to damage to the growth factor by repeated freezing or thawing. This explanation was 
previously proposed by Parker et al.[337] Another possible explanation is that the growth factor 
lost its functionality by autolysis, as proposed by Nicoll et al.[339]  While the loss of bioactivity 
over time will be addressed in future studies, we are optimistic that our fabrication protocol does 
not affect the bioactivity of TGF-β1. 
4.5 CONCLUSIONS 
Biodegradable PEG-based hydrogels containing TGF-β1-loaded PLGA microspheres 
were developed with potential utility in cartilage tissue engineering. The controlled release of 
TGF-β1 from microspheres embedded in the hydrogels is further controlled when compared to 
delivery from microspheres alone, resulting in a delayed burst release. ELISA results indicated a 
continued release of TGF-β1 up to 21 days from the PEG-genipin hydrogels. Mink lung cell 
growth inhibition results indicated bioactivity decreased after 7 days, but remained fairly 
constant throughout the study. The release of TGF-β1 was more controlled from PEG-genipin 
low hydrogels as compared to PEG-genipin high hydrogels. Finally, the scaffold permits 
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containment and conformation of the spheres to the defect shape, which is highly useful for in 
situ chondrogenesis.  
4.6 FUTURE DIRECTIONS 
We successfully developed a system to locally deliver TGF-β1 for cartilage tissue 
regeneration.  However, more research must be done to further establish this delivery system for 
cartilage repair.  The efficiency of this delivery system to induce chondrogenesis of bone marrow 
stem cells should be investigated.  This can be demonstrated in vitro with the use of Transwell 
inserts.  Another step can then be taken by encapsulating cells within the polymer.  The current 
PEG-genipin system is not adequate for cell encapsulation, but utilizing a 4-arm or 8-arm amino 
terminated PEG may be more sufficient (See Chapter 5).   The use of this delivery system must 
be investigated in vivo.  We examined the use of PEG-genipin scaffolds alone in osteochondral 
defects of rats (Appendix C).  However, this animal model has a small defect (diameter = 
1.5mm).  Incorporating an adequate amount of microspheres to release a sufficient amount of 
TGF-β1 would be impossible.  This could be overcome by utilizing a larger animal model and 
thus a larger defect.  Large animals such as dogs, goats, and horses more closely resemble the 
human model, leading to a better study.[340]  Another possibility would be to increase the 
encapsulation efficiency of the PLGA microspheres.  While this area has been widely studied, 
the results are contradicting.  The encapsulation efficiency is dependent upon many factors 
including nature of the polymer, concentration of polymer, surfactant utilized, solvent removal 
rate, ratio of lactic acid and glycolic acid, and temperature (See Chapter 1).[341, 342]   
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5.0  MODIFICATIONS OF PEG-GENIPIN TO INCREASE GELATION RATE 
5.1 INTRODUCTION 
Hydrogels can be utilized as delivery systems, cell carriers, and scaffolds for tissue 
engineering.  Injectable hydrogels allow easy and homogenous drug or cell distribution within 
any size or shape defect.  Our goal was to modify the PEG-genipin hydrogels previously 
described in Chapter 4.  The PEG-genipin hydrogels utilized in Chapter 4 were fromed over two 
days.  We aimed to develop a hydrogel that will gel in situ utilizing PEG and genipin, by 
decreasing the gelation time of the current hydrogel.   An injectable hydrogel could be utilized to 
encapsulate both cells and microspheres for tissue engineering.  We examined the modification 
of the PEG diamine-genipin hydrogels.  First we examined the structure of genipin and further 
characterized the PEG diamine-genipin hydrogels.  The gelation time was decreased by exposure 
of the PEG-genipin solution to air and by exposure of the genipin solution to oxygen.  We then 
examined the effects of the structure of PEG on the gelation rate.  Multi-branched PEG was 
examined for this study.  We examined diamine PEG (previously used in Chapter 4), 4-arm PEG, 
a molecule with 4 PEG chains attached at a central point, and 8-arm PEG, a molecule with 8 
PEG chains attached to a central molecule.  By utilizing amino-terminated multi-branched PEG, 
the number of amine groups for the genipin to react with would increase.  The gelation time was 
decreased by utilizing a 4-arm PEG compared to a 2-arm or 8-arm PEG.  The results lead to a 
 105 
further understanding of the PEG-genipin hydrogels and modifications of parameters to decrease 
the gelation time.   
5.1.1 Genipin 
As previously mentioned, genipin reacts with primary amine groups.  Genipin is isolated 
from the fruits of Genipa americana and Gardenia jasminoides Ellis.[343]  Genipa Americana is 
found in tropical America, from Mexico to Argentina and the Caribbean.  Gardenia jasminoides 
is located in the Far East.  Both fruits have been utilized as diuretics, anti-inflammatory 
medication, and to treat jaundice and hepatic diseases.[343] The fruit of Genipa americana has a 
white flesh that turns to yellow to bluish-purple then to jet-black upon exposure to air.[344]  This 
colorimetric change is similar to what is observed with the reaction of genipin and PEG-diamine 
(Figure 5-1).  Eight iridoid glucosides have been extracted from the fruit including, genipin, 
geniposidic acid, and geniposide.[344]   
 
Figure 5-1.  Colorimetric changes of PEG-genipin. 
 
The use of genipin as a crosslinker is advantageous over glutaraldehyde, a commonly 
used crosslinker.  Genipin is less cytotoxic[331, 332, 345] and genotoxic than 
glutaraldehyde.[331]  Implantation of genipin crosslinked scaffolds has shown that they are 
biocompatible.[346] Materials resulted in minimal foreign body reaction[347] and less 
inflammation occurred in gelatin-genipin scaffolds than gelatin crosslinked with 
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glutaraldehyde.[348]  Genipin has been observed to have anti-inflammatory effects.[349]  To 
further confirm its biocompatibility, genipin crosslinked materials have been used to encapsulate 
cells.[347]  Similarly, cells adhere to materials crosslinked with genipin better than materials 
crosslinked with glutaraldehyde.[345, 350]  Due to these advantages a variety of materials 
crosslinked with genipin have been studied (Table 5-I). 
Table 5-I.  Genipin crosslinked materials. 
Chitosan [235, 330, 343, 345, 347, 351-354] Collagen [355, 356] 
Albumin [343, 357] PEG-diamine [25, 335, 358] 
Gelatin [343, 346, 348, 354, 359-362] Cartilage [363] 
Pericardia [332, 350, 364, 365]  
 
The reaction of genipin with primary amines has been well studied.  Genipin was found 
to only react with primary amine groups.[332] Park et al. examined the reaction of methylamine 
and genipin.[366]  They proposed the mechanism of the reaction seen in Figure 5-2.  Genipin has 
been observed reacting in one of two schemes (Figure 5-3).[343]  Chen et al. demonstrated that 
genipin reacted with two chitosan molecules, thus having two functional sites.[353]  However, 
the dimerization of genipin has also been observed.[354, 367]  The dimerization and 
polymerization of genipin was further confirmed when Butler et al. observed the polymerization 
of genipin during reaction with BSA in water.[343]  The polymerization of genipin was also 
observed by Mi et al.[351]  This study demonstrated the formation of dimers, trimers, tetramer 
bridges, and polymerization of genipin. 
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 Figure 5-2. Reaction of genipin with methylamine.[366] 
 
 
Figure 5-3.  Reaction schemes of genipin with primary amine groups.[343] 
Additional parameters affecting the reaction times of genipin with materials have been 
investigated.  The main observation is that the genipin reaction occurs faster at the interface with 
air.[343, 344, 347]  Reactions in water occurred quicker than in deuterium oxide, thus 
demonstrating that the reaction may require acid catalysis.[343]  The reaction occurs quickest at 
a temperature of 37oC.[347, 352] In this study we examined some of these parameters to increase 
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the gelation rate.  Specifically we examined temperature, exposure to air, exposure to oxygen, 
and PEG structure. 
5.1.2 4-arm and 8-arm PEG 
Recently, multi-branched PEG polymers have gained interest.[368-370]  The multi-
branched PEGs have been used as cell scaffolds,[326] in situ forming hydrogels,[371, 372] 
adhesive medical applications,[373] and as delivery vehicles.[372, 374-378]  Examination of 
diamine, trisamine, and 4-arm amine PEG polymers effects on ECV 304 cells (human umbilical 
vein endothelial cells) demonstrated that the polymers were not cytotoxic up to a concentration 
of 4mg/mL.[378]  
In this study, we examined the use of amine terminated 4-arm and 8-arm PEG (Figure 5-
4).  By increasing the number of functional amine groups genipin can react with, we 
hypothesized the gelation time will decrease. 
 
Figure 5-4.  Structure of 4-arm aminated PEG (a) and 8-arm aminated PEG (b). 
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 5.2 METHODS 
5.2.1 Genipin characterization 
Pure genipin was characterized as a solid.  Genipin was characterized utilizing Fourier 
Transform infrared spectroscopy (FT-IR) and 1H Nuclear Magnetic Resonance (NMR). FT-IR 
was performed on genipin dissolved in chloroform (in the Department of Chemistry at the 
University of Pittsburgh).  For NMR analysis, genipin was dissolved in deuterated water (D2O).  
The solution was then analyzed utilizing 300MHz spectrometer (in the NMR facility in the 
Department of Chemistry at the University of Pittsburgh).   
5.2.2 PEG diamine-genipin characterization 
We examined the PEG diamine-genipin hydrogels utilizing SEM.  Hydrogels were 
swelled in water, frozen, and freeze-dried.  The hydrogels were then gold coated using a 
Cressington 108 Auto (Cressington, Watford UK).  Hydrogels were viewed using a JSM-6330F 
scanning electron microscope (JEOL, Peabody, MA) operated at 10 kV accelerating.  The 
porosity of the PEG-genipin scaffolds was determined from the SEM images utilizing Image J 
Software (NIH, USA). 
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5.2.3 Cell adhesion to PEG diamine-genipin hydrogels 
Cell adhesion to the PEG diamine hydrogels was assessed using two different cell types. 
Human adipose derived stem cells (ASCs) were plated at a density of 20,000 cells per well in 
ASC medium on PEG-genipin hydrogels, control wells (polystyrene tissue culture treated wells), 
and poly(caprolactone) (PCL) disks.  After 5 hours, viable cells were measured using the MTS 
assay (Cell Titer96 Proliferation Assay, Promega Corp, Madison, WI). The attachment of bone 
marrow-derived mesenchymal cells (BMSCs) was also determined.  BMSCs at a concentration 
of 10,000 cells/mL were plated on PEG-genipin hydrogels and PCL disks.  After 5 hours, viable 
cells were determined utilizing the MTS assay. 
5.2.4 Modifications to decrease gelation time 
Since an in situ gelling hydrogel is desired, we examined possible ways to increase the 
gelation rate (decrease gelation time) of the PEG-diamine genipin hydrogels.  Other investigators 
and ourselves have observed that exposure of genipin to air enhanced the reactions with 
amines.[343, 344, 347] PEG-genipin, yielding a final concentration of 35.2mM genipin was 
prepared. The solution was exposed to air to decrease the gelation time.  The solution was 
allowed to react in a closed system (sealed vial), an open system (vial open to environment), or 
an open system exposed to air, by bubbling air through the solution (exposed).  The PEG-genipin 
solutions were monitored for gelation.  Gelation was initialized when the solutions became blue.  
Modifying the genipin solution before reaction with the PEG solution was also analyzed.  The 
genipin solution was modified by exposure to oxygen.  The genipin solution (88mM) was 
exposed to oxygen for 0, 10, or 30 minutes (Figure 5-5).  The modified genipin solutions were 
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then added to PEG solutions, yielding a final concentration of 44mM.  The PEG-genipin 
solutions were monitored for initialization of gelation. 
 
Figure 5-5.  Setup for oxygenation of genipin (a), schematic of setup (b). 
5.2.5 Multi-arm PEG-genipin synthesis 
PEG 4-arm and PEG 8-arm (Jenkem Technology, Beijing, China) 10% (w/v) solutions 
were prepared.  The PEG solutions were then crosslinked with 88mM genipin solutions for final 
concentrations of 8mM, 12mM, 15mM, 17.6mM, 25mM, and 35.2mM.  The gelation times were 
recorded.  Gelation was monitored at 25oC and 37oC of 4-arm PEG-genipin.   
5.2.6 Multi-arm PEG-genipin hydrogel characterization 
The PEG-genipin hydrogels (4-arm 35.2mM and 17.6mM, 8-arm 35.2mM and 17.6mM, 
and 2-arm 35.2mM) were characterized after gelation.  The dissolution times were monitored.  
PEG-genipin hydrogel disks were punched out using a 6mm dermal biopsy punch.  The disk 
initial weight, diameter, and height were measured. The disks were placed in 1mL PBS in 
microcentrifuge tubes.  At each time point (1 day, 1 week, 3 weeks, 6 weeks, and 12 weeks) the 
wet weight, diameter, and height of the hydrogels were measured.  The hydrogels were removed 
from the PB and then freeze-dried. The dry weight was measured and then the hydrogels were 
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analyzed using SEM.  The water uptake and diameter change were calculated utilizing the 
following equations: 
Water uptake ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −×=
tdry
tdrytwet
m
mm
%100  Equation 5-1 
Diameter change ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −×=
0
0%100
d
ddt  Equation 5-2 
Where mtwet is the wet weight of the scaffold at time t and mtdry is the dry weight of the 
scaffold at time t.  For the diameter change, dt is the diameter at time t and do is the diameter at 
time 0.   
5.2.7 Statistical analysis 
Student’s t-tests were performed when comparing two groups or two time points.  A 
statistical difference was determined by p<0.05. 
5.3 RESULTS 
5.3.1 Genipin characterization 
Genipin was characterized utilizing FT-IR.  The spectrum is shown in Figure 5-6.  The 
position and intensity of the peaks are listed in Table 5-II.  The peaks at 3400.16cm-1 and 
3270.39cm-1 represent alcohol groups.  The peak at 1106.11cm-1 is the C-O-C stretch and 
1626.10cm-1 the C=C stretch.  The peak at 1686.30cm-1 indicates the ester peak. 
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 Figure 5-6.  IR spectra of genipin. 
Genipin was also characterized utilizing 1H NMR.  The resulting spectrum is shown in 
Figure 5-7.  The chemical structure of genipin and corresponding positions are shown in Figure 
5-8.  
 
Figure 5-7.  NMR spectra of genipin. 
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 Figure 5-8.  1H NMR data of genipin. 
5.3.2 PEG diamine-genipin characterization 
PEG-diamine genipin scaffolds were swelled in water, frozen, and freeze-dried.  The 
SEM images of the scaffolds demonstrate a porous scaffold (Figure 5-9).  The PEG-genipin 
scaffolds had an average porosity of 43.67 ± 10.36% (n=5). 
a b
 
Figure 5-9.  SEM of PEG diamine-genipin (a) and under higher magnification (b). 
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5.3.3 Cell adhesion on PEG diamine-genipin hydrogels 
Previously the adhesion of smooth muscle cells to PEG-genipin gels was 
characterized.[25]  No significant difference was seen between adhesion to the PEG-genipin 
hydrogels and the control wells (TCP).  We observed similar results with the adhesion of human 
ASCs and BMSCs.  There was no significant difference between the adhesion of ASCs on PEG-
genipin scaffolds and the tissue-culture treated wells (Figure 5-10).  However a significant 
difference was seen compared to PCL disks, with increased adhesion on the PEG-genipin disks.  
The adhesion of BMSCs resulted in a significant increase in cell adhesion on PEG-genipin 
scaffolds compared to the PCL disks (Figure 5-10).   
 
Figure 5-10.  Adipose derived stem cell adhesion (a) and bone marrow stem cell adhesion (b). 
*p<0.05 compared to PEG-genipin and TCP (a).  *p<0.05 compared to PCL. 
5.3.4 Decrease of gelation time 
Exposure of the PEG diamine-genipin hydrogels to air and oxygen decreased the gelation 
times.  During the reaction of the PEG diamine and genipin solutions, the solution will change 
colors, beginning as a clear solution and ending in a blue solution.  The initialization of gelation 
was determined when the solution became dark blue.  Exposure of the PEG-genipin solution to 
air decreased the gelation time (Figure 5-11). 
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Figure 5-11.  Time for initialization of gelation of PEG-genipin exposed to air. 
A clinically applicable in situ gelling hydrogel is desired. As we observed a decrease in 
gelation times by exposure to air, we hypothesized that the oxygen in air was increasing the 
gelation rate.  We wanted to decrease the gelation time by modifying the genipin solution.  
Therefore, we exposed the genipin solution to oxygen and then reacted the exposed genipin with 
PEG solutions.  The gelation times of PEG-genipin hydrogels was reduced when the genipin 
solution was exposed to oxygen (Table 5-II).  As exposure to oxygen was increased, the gelation 
time decreased. 
Table 5-II.  Initialization of gelation of PEG-genipin after oxygen exposure. 
Time of treatment 
with Oxygen (min) 
Time for solution to 
become blue (hr:min) 
0 4:22 
10 2:22 
30 1:37 
5.3.5 Gelation of multi-arm PEG-genipin 
The gelation rate of multi-arm PEG-genipin hydrogels was monitored.  Increasing the 
concentration of genipin decreased the gelation time.  The gelation rate of the 4-arm hydrogels 
was quicker than the 8-arm hydrogels (Table 5-III).  For both the 4-arm and 8-arm PEG, the 
8mM concentration of genipin never gelled, the solution became blue, but a gel was not formed.  
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Thus, all subsequent studies were performed on the 4-arm hydrogels only.  Increasing the 
temperature from 25oC to 37oC, led to a decrease in gelation times (Figure 5-12).   
Table 5-III.  Gelation times of 4-arm and 8-arm PEG at 25oC. 
Genipin 
Concentration 
(mmol) 
4-arm gelation 
time (hours) 
8-arm gelation 
time (hours) 
12 >8 >8 
15 6.53 ± 0.21 >8 
17.6 5.50 ± 0.87 >8 
25 3.59 ±  0.58 17 ± 8.23 
35.2 2.92 ±  0.63 6.52 ±  1.93 
 
 
Figure 5-12.  Gelation times of 4-arm PEG at 37oC (■) and 25oC(□).   
All values reported as means ± standard deviations (n=3).  *p<0.05. 
5.3.6 Characterization of multi-arm PEG-genipin hydrogels 
The dissolution of the scaffolds was determined by examination at various times.  At time 
point 1 week, the 8-arm 17.6mM scaffolds were not able to be weighed because they had begun 
dissolution.  At this point, the scaffolds were a viscous liquid, and not a gel.  At 12 weeks, the 
8-arm 17.6mM scaffolds were the only scaffold samples to have degraded.  
The water uptake of the hydrogels was calculated utilizing equation 5-1.  The water 
uptake was dependent on the structure of the PEG (Table 5-IV).  The water uptake within the 4-
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arm PEG on the first day was significantly higher than the 2-arm or 8-arm PEG.  At one week 
and 12 weeks, the water uptake was higher in the 4-arm PEG than 8-arm PEG hydrogels.  For 
weeks 3 and 6, both the 2-arm and 4-arm PEG hydrogels demonstrated a significant increase in 
water uptake compared to the 8-arm PEG hydrogels. 
Table 5-IV.  Water uptake of hydrogels. 
Water uptake 1 day 1 week 3 weeks 6 weeks 12 weeks 
2-arm 35.2mM 686.78 ± 70.98 809.97 ± 61.66 
839.84  ± 
88.36* 
885.30  ± 
100.58* 
841.16  ± 
143.47 
4-arm 35.2mM 
1808.94 ± 
174.11** 
1094.43 ± 
137.63* 
851.57 ± 
10.56* 
875.89 ± 
106.46* 
993.20 ± 
83.21* 
8-arm 35.2mM 
710.41 ± 
234.81 710.41 ± 58.52 
605.14  ± 
23.78 607.95  ± 67.81 
607.70  ± 
69.42 
**p < 0.05 compared to 2-arm and 8-arm PEG. 
*p< 0.05 compared to 8-arm PEG. 
 
The water uptake was also dependent upon the genipin concentration.  A lower genipin 
concentration (17.6mM) resulted in an increased water uptake at all times point past one day 
(Table 5-V).  Since the 17.6mM hydrogels are less crosslinked, the water uptake should be 
higher.  
Table 5-V.  Effects of genipin concentration on water uptake. 
Water uptake 1 day 1 week 3 week 6 weeks 12 weeks 
4-arm 35.2mM 
1808.94 ± 
174.11 
1094.43 ± 
137.63* 
851.57 ± 
10.56* 
875.89 ± 
106.46* 
993.20 ± 
83.21* 
4-arm 17.6mM 
1715.63 ± 
420.69 
1877.08 ± 
174.47 
1742.62 ± 
79.33 
1971.74 ± 
347.56 
1987.42 ± 
51.02 
*p<0.05 between 35.2mM and 17.6mM genipin concentration 
The swelling ratio of the hydrogels was examined.  The diameter change was calculated 
by equation 5-2.  No significant differences were observed between the 8-arm and 4-arm 
35.2mM hydrogels(Figure 5-13).  The diameter change of the 4-arm 17.6mM and 2-arm 35.2mM 
could not be compared to the 35.2mM 4-arm and 8-arm because the scaffolds were partially 
dehydrated and thus swelled in one direction (diameter) instead of all directions (Figure 5-14). 
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 Figure 5-13.  Diameter change of PEG-genipin hydrogels. 
Diameter change of 35.2mM 4-arm PEG hydrogel (-■-) and 35.2mM 8-arm PEG hydrogel (-▲-).  All values 
reported as means ± standard deviations (n=3). 
 
Figure 5-14.  Swelling of PEG-genipin scaffolds.   
2-arm 35.2mM hydrogel before and after immersion in water (a).  4-arm 35.2mM hydrogel before and after 
immersion in water (b) and (c). 
5.4 DISCUSSION 
An injectable hydrogel is clinically desired as the system could result in minimally 
invasive surgeries.  Hydrogels that gel in situ could fill a defect of any size or shape.  The 
hydrogel can be utilized for cell delivery, as well as growth factor or drug delivery. In this 
chapter we examined methods to modify PEG-genipin hydrogels to decrease the gelation time, 
thus increasing the gelation rate.   
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The structure of pure genipin was first examined by 1H NMR and FT-IR.  Utilizing these 
methods we gained a further understanding of the crosslinking mechanism of genipin with 
aminated PEG.  Of particular interest was the fact that hydrogels were formed with the reaction 
of genipin with PEG diamine.  For this to occur, genipin must have three functional groups or 
react with itself to form three functional groups to react with PEG diamine. A similar observation 
was seen by Lee et al.  Their study examined the gelation of 4-arm PEG amine, linear 2-arm 
PEG diamine, and methoxy-PEG-amine with 3,4-dihydroxyphenylalanine (DOPA).[373]  All of 
the formulations formed gels except for the methoxy-PEG-amine, thus the authors state that 
DOPA must react with itself to combine at least three residues to form a gel with the bis-amine 
PEG.  The dimerization of genipin has been observed by many groups.[343, 351, 354, 367, 379]  
Also of importance, the polymerization of genipin was observed by Mi et al. and Butler et al., 
demonstrating that genipin can form trimers and tetramer bridges to react with multiple amine 
groups.[343, 351] 
We observed that the reaction of PEG diamine was quicker at the interface of the gel and 
the air.  This has also been noted by others.[343, 344, 347]  We were able to decrease gelation 
time by exposing the PEG-genipin solution to air.  We then examined the modification of 
genipin by exposure to oxygen, and the gelation time was decreased.  The reaction of genipin 
with amine groups and the formation of dimers and polymerization has been observed to be 
oxygen radical-induced.[343, 345, 351, 367]  This may explain why the exposure to oxygen 
decreased gelation time.   
Our hypothesis was that the 8-arm PEG would react quicker with the genipin than the 4-
arm PEG, resulting in a faster gelation rate.  However, the opposite was observed.  There are two 
possible explanations for this phenomenon.  First, by examining the reaction of genipin with 
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different molecules,  Mi et al. observed that the reaction with gelatin was slower than chitosan, 
as chitosan has more available reaction sites (i.e., amino functionalities).[354]  However, when 
Butler et al. examined the gelation of genipin with chitosan, BSA, and gelatin, their study 
demonstrated that the structure of the molecule reacting with genipin was more important than 
the number of primary amines.[343]  In our study, the gelation rate was quicker with 4-arm PEG 
than the 8-arm PEG.  This is most likely due to the structure of the 8-arm PEG.  This leads to the 
examination of 8-arm PEG.  Similar to our study, Lee et al. observed that the gelation of 4-arm 
PEG amine and DOPA was quicker than the linear bis-amine PEG and DOPA.[373]  We also 
reported a decrease in gelation time of the 4-arm PEG compared to the 8-arm PEG and 2-arm 
PEG with genipin.  Lin et al. examined the properties of copolymers of PEG and poly(N-
isopropylacrylamide) (PNIPAAM).  As the number of arms increased from one to two to four, 
the strength and deformability increased; however, the mechanical properties decreased when 8-
arm structures were examined.[380]  They explain this phenomenon due to intramolecular 
aggregation which prevented crosslinking of the chains.  In another study, Dai et al. analyzed the 
interaction between sodium dodecyl sulfate (SDS) and different PEG structures.  The structures 
of two, three, four, and eight arm PEG were examined.  They examined the saturation 
concentration of all of the PEG structures and saw similar values for the two, three, and four arm 
PEG, but a much lower value for the 8-arm PEG.  They also explain this phenomenon on the 
structure.  The 8-arm PEG has a more compact structure and thus gives rise to a smaller binding 
capacity.  In our study, we observed a much slower reaction with the 8-arm PEG than the 4-arm 
PEG.  We also believe this to be due to the structure of PEG and the ability of genipin to react 
with the amine groups.   
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5.5 CONCLUSIONS 
We examined the modification of experimental parameters of PEG-genipin reaction in an 
attempt to decrease gelation time.  We characterized the PEG diamine-genipin hydrogels.  Adult 
stem cells adhere to the hydrogels, thus they may provide an alternative to current cell scaffolds.  
However, an in situ gelling hydrogel is clinically desired and may have immense impacts in the 
area of tissue engineering.  We have examined the use of natural and synthetic scaffolds (gelatin 
and PEG-genipin), neither of which is an injectable hydrogel.  Therefore, we analyzed methods 
to reduce the gelation time of the current PEG-genipin scaffolds.  We demonstrated a decrease 
in gelation time by exposure of PEG-genipin solution to air, as well as a decrease due to 
exposure of genipin to oxygen.  We then examined the use of multi-branched PEG.  A decrease 
in gelation time was observed in both the 4-arm and 8-arm PEG compared to the linear (2-arm) 
PEG.  However, the gelation time was most reduced by use of the 4-arm PEG.  The gelation 
occurred more quickly by increasing the temperature from 25oC to 37oC. Important, initial steps 
to decrease the gelation time were demonstrated in this study.         
5.6 FUTURE DIRECTIONS 
We have demonstrated methods to decrease the gelation time of PEG-genipin scaffolds.  
We examined the use of 4-arm and 8-arm PEG.   Our results revealed that the structure of PEG 
was an important factor in gelation time.  By examining other PEG structures, such as 3-arm 
and 6-arm PEG, these can be further explored.  We also demonstrated a decrease in gelation 
time of the PEG diamine-genipin by exposing the genipin to oxygen.  A similar experiment may 
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be performed with the multi-branched PEG.  A further understanding of the genipin 
modification occurring during exposure to air and oxygen is required as well as the reaction 
with aminated PEG.  Finally, solid state NMR could be performed on the scaffolds to further 
analyze this reaction.   
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6.0  OVERALL CONCLUSIONS 
Delivery systems have been investigated to control the delivery of proteins or drugs.  
Delivery systems can provide protection of the drug, maintain desired levels of the drug, prolong 
the release, localize delivery, and decrease adverse side effects.  The overall goal of this thesis 
was to examine PLGA microspheres as delivery systems in tissue engineering applications.  We 
have created novel delivery systems for each of the applications.   
The study presented in Chapter 2 demonstrated the use of PLGA microspheres as an 
injectable delivery system to create and maintain the desired microenvironment in vivo.  We 
demonstrated that FGF-2 released from PLGA microspheres could induce ASC proliferation and 
increase survival in vitro.   The results of a 14 day in vitro study in the absence of serum 
confirmed that delivery of FGF-2 from microspheres was superior to a repeated bolus of free 
FGF-2.  Based on these findings, we examined the effects of FGF-2 microspheres on ASC 
survival in vivo.  Although no difference was observed on cell survival after two weeks, a 
difference was observed in the angiogenesis of the surrounding area.  The number of blood 
vessels present was significantly increased in the mice treated with FGF-2 microspheres.  
Angiogenesis provides nutrients and waste removal, and thus is an important factor in cell and 
tissue survival in vivo.  After two weeks, no adipogenesis was seen in any of the groups.   
Since we did not observe mature adipocytes derived from our injected ASCs, we 
investigated the delivery of adipogenic factors to induce differentiation.  Insulin and 
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dexamethasone were encapsulated in PLGA microspheres.  The adipogenesis of ASCs was 
induced by replacing dex and insulin in media with the corresponding PLGA microspheres.  
Adipogenesis was confirmed by oil red O staining and expression of PPAR-γ.   
The results of this study have implications for new clinical therapies in soft tissue 
reconstruction.  An injectable engineered soft tissue replacement can be used to reconstruct a 
defect.  The success of this replacement would depend on successful vascularization and 
differentiation of the stem cells.  Including FGF-2 microspheres with the cells and scaffold 
mixture would not only enhance survival of the implanted cells, but could decrease the time 
required for successful vascularization and accelerate the treatment process.  These injections 
could be followed by dex and insulin microspheres to enhance adipogenesis of the cells.  
Chapter 3 presents a study in which a novel delivery system to locally deliver a 
chemotherapeutic agent as well as maintain the contour of the breast following a lumpectomy 
was developed.  In this chapter we examined a delivery system in which PLGA microspheres 
were embedded within a gelatin scaffold.  The gelatin scaffold was utilized to further control the 
release of the chemotherapeutic agent as well as provide structure to the defect.  The delivery 
system was utilized to maintain local levels of the drug that have adverse side effects when 
delivered systemically. The release was further controlled by the incorporation of PLGA 
microspheres into gelatin constructs.  The efficacy of released doxorubicin from the 
microspheres and the gelatin scaffolds to kill tumor cells was demonstrated in vitro.  
The delivery system we developed was successful in vitro, thus in vivo studies were 
subsequently performed.  The animal model utilized simulated a lumpectomy; at the time of 
inoculation of tumor in the mammary fat pad, the mice were treated with gelatin scaffolds.  
Implantation of the 2Dox scaffold resulted in tumor eradication.  No adverse reactions were 
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observed in the mice due to treatment with the 2Dox scaffolds even though a large dose of dox 
was delivered. 
 The results of Chapter 3 demonstrate a potential alternative adjuvant treatment for breast 
cancer patients following a lumpectomy.  A scaffold that promotes tissue ingrowth and 
temporarily maintains breast contour can be utilized as the delivery system.  Dox-loaded PLGA 
microspheres embedded within the scaffold locally release Dox to kill any remaining tumor cells.  
An implantable chemotherapy delivery system can possibly reduce the local recurrence rate 
following surgery.  An unmet need to improve the current therapy for not only breast cancer but 
other malignancies as well exists.  We have developed a novel delivery system by embedding 
synthetic polymer microspheres within a natural hydrogel at the time of fabrication that may lead 
to improvement of these current therapies.  
The next study presented in Chapter 4 described the development of a delivery system 
incorporating PLGA microspheres within in a novel synthetic hydrogel.  Biodegradable PEG-
based hydrogels containing TGF-β1-loaded PLGA microspheres were developed with potential 
utility in cartilage tissue engineering.  The release of TGF-β1 was further controlled when the 
microspheres were incorporated in the hydrogel compared to microspheres alone.  The results 
indicate that the release can be further modified by changing the genipin concentration of the 
PEG-genipin hydrogels.  The bioactivity of the released TGF-β1 was confirmed utilizing a mink 
lung inhibition assay.   
The development of this delivery system permits a scaffold to be placed in the cartilage 
defect and containment of the microspheres within the hydrogel.  The concentration of released 
TGF-β1 can be determined by the amount of microspheres and genipin concentration of the 
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hydrogels.  This is important because use of this delivery system in vivo can be utilized to 
determine the effects of released TGF-β1 in cartilage repair.   
The final study presented in Chapter 5 focused on developing a hydrogel that could gel in 
situ.  The clinical applications of this are of immense importance.  Defects in soft tissue or 
cartilage tissue are not of uniform shape, thus a hydrogel that can fill in any size and shape defect 
is highly desired.  We demonstrated that the gelation time of PEG-genipin scaffolds can be 
reduced by modification of the parameters involved.  Exposure of the PEG-genipin solution to 
air and the genipin solution to oxygen before the reaction occurred decreased the gelation time.  
The PEG structure also affected the gelation time.  The 4-arm PEG gelled most rapidly compared 
to 2-arm and 8-arm PEG.  Finally, the reaction occurred quicker at 37oC compared to 25oC.  
These steps demonstrated modification of the parameters can decrease the gelation time.   These 
results also reveal insights into the reaction between genipin and PEG, gaining a further 
understanding of the mechanism.  
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APPENDIX A 
ADIPOSE DERIVED STEM CELL PLASTICITY 
The plascity of ASCs has been examined by many investigators. As mentioned in 
Chapter 2, the plasticity of ASCs into all three lineages has been demonstrated.  The following 
tables outline the differentiation of ASCs and their references cited.  These tables correspond to 
Figure 2-1. 
Appendix Table I.  ASC differentiation into endodermal lineage 
In Vitro In Vivo 
Hepatocytes [381, 382] Hepatocytes [382] 
Epithelial Cells [383]  
Pancreatic Islets [384]  
 
Appendix Table II.  ASC differentiation into mesenchymal lineage. 
In Vitro In Vivo 
Adipocytes [1, 2] Adipocytes [184, 385] 
Endothelial Cells [3, 4] Endothelial Cells [3, 4] 
Muscle Cells [1, 2, 386] Muscle Cells [387] 
Osteoblasts [1, 2, 107] Osteoblasts [388, 389] 
Chondrocytes [1, 2, 93, 390] Chondrocytes [42, 101, 389, 390] 
Bone Marrow Cells [391] Bone Marrow Cells [391] 
Cardiomyocytes [392-394] Cardiomyocytes [395-397] 
Smooth Muscle Cells  
 
Appendix Table III.  ASC differentiation into ectodermal lineage. 
In Vitro In Vivo 
Neuronal [2, 398-400] Neuronal [401] 
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APPENDIX B 
CISPLATIN ENCAPSULATION 
B.1 INTRODUCTION 
We have demonstrated the release of doxorubicin from PLGA microspheres.  Other 
chemotherapeutic agents can be encapsulated in a similar manner to be embedded within the 
gelatin scaffolds.  Cisplatin is a platinum based chemotherapeutic drug (App Figure 1). As 
previously mentioned, chemotherapeutics have adverse side reactions that may be overcome by 
local controlled delivery.  Cisplatin has been delivered from PEG hydrogels,[402] polymer 
microspheres,[403-408] PLA,[409] and gelatin.[228] 
 
 
  
Appendix figure 1.  Structure of cisplatin 
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B.2 METHODS 
Cisplatin was encapsulated in PLGA (75:25) microspheres utilizing a modified 
protocol.[406]  Briefly, 500mg PLGA was dissolved in methylene chloride.  Cisplatin (15mL of 
1mg/mL cisplatin) was added to the dissolved polymer.  This emulsion was then added to the 
aqueous phase (0.15 w/v% PVA and 0.05 w/v% methyl cellulose in distilled water) which was 
saturated with 30mg of cisplatin.  The mixture was then stirred for 4 hours at 500rpm.  The 
microspheres were collected by centrifugation, washed with DI water, frozen, and lyophilized.  
The microspheres were examined morphologically by SEM.  The images were also used to 
determine the diameter distribution of the microspheres.   
Cisplatin microspheres were placed in microcentrifuge tubes with 1mL of PBS and 
incubated at 37oC.  At various time points the tubes were centrifuged, the supernatant removed, 
and analyzed for released cisplatin.  The tubes were refreshed with PBS.  The released cisplatin 
was measured by reacting with sodium diethyldithiocarbamate (NaDDTC) solution (1mol 
NaDDTC to 10mol cisplatin) with the samples.  The pH was adjusted to 8.0 and the samples 
were stirred for 24 hours.  The precipitate was vacuum-dried and then dissolved in 1mL MC.  
The absorbance of the resulting solution was measured on a spectrophotometer at 347nm.   
B.3 RESULTS AND DISCUSSION 
Cisplatin was encapsulated in PLGA microspheres.  The microspheres exhibited a round 
smooth morphology (Appendix Figure 2).  The average diameter of the microspheres was 
115.5µm, with the diameter distribution as seen in Appendix Figure 3. 
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 Appendix figure 2.  SEM of cisplatin-loaded PLGA microspheres. 
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Appendix figure 3.  Diameter distribution of cisplatin-loaded microspheres. 
The method to analyze the released cisplatin had its limitations.  Thus the release could 
only be detected up to day 17 (App Figure 4).  Since this method is not sensitive enough to 
determine low amounts, caution should be taken to rely on these results. Another method should 
be utilized to determine the release.  Reliable results utilizing atomic absorption 
spectrophotometry, which detects platinum, have been observed.[228, 410, 411]  This could be a 
possible method to detect the release cisplatin. Another method is measuring the cisplatin 
utilizing colorimetric oPDA method as described in articles from Gemeinhart’s lab.[402, 403] 
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Appendix figure 4.  Cumulative release of cisplatin. 
All results reported as means ± standard deviations. (n=3) 
 
We encapsulated cisplatin in PLGA microspheres.  We were unable to successfully 
determine the release kinetics.  However, other methods to detect released cisplatin have been 
suggested.  Once the release kinetics have been determined, cell studies similar to those in 
Chapter 3 should be performed to assess the effectiveness to kill tumor cells.  Then the efficacy 
of the gelatin scaffolds loaded with both doxorubicin and cisplatin microspheres to ablate tumors 
in vitro and in vivo should be assessed. 
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APPENDIX C 
IN VIVO DISSOLUTION OF PEG-GENIPIN HYDROGELS WITHIN 
OSTEOCHONDRAL DEFECTS 
C.1 INTRODUCTION 
PEG hydrogels show promise as scaffolds for growth factor delivery to enhance cartilage 
repair.  We have demonstrated that we can control the release of TGF-β1 from PLGA 
microspheres by incorporating microspheres in PEG-genipin hydrogels and further alter these 
kinetics by changing the crosslinker concentration (Chapter 4).  However, the in vivo behavior 
and dissolution of PEG-genipin hydrogels within the osteochondral defect was unknown.  
Therefore, we conducted the in vivo study described below. 
C.2 METHODS 
PEG-genipin hydrogels were prepared as described previously (Section 4.2.1).  PEG 
solutions were crosslinked with genipin to yield final concentrations of 8mM, 17.6mM, and 
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35.2mM genipin.  Once the solutions turned blue, the solutions were pipeted into Teflon molds 
with a diameter of 1mm and 1mm in height (Figure C1).  
1mm 
1mm 
                 
Appendix figure 5.  Diagram of PEG-genipin plug. 
Twenty-four male Sprague-Dawley (Harlan Laboratories, 12 weeks old) rats were 
anesthetized with 50 mg/kg of Nembutal (Abbott Laboratories, North Chicago, IL, USA). Lateral 
parapatelar incisions were performed. The patella was dislocated to the medial sides and the 
trochlea was exposed. A defect of 1.5 mm2 was created bilaterally in the trochlea by drilling. The 
rats were divided into three different groups. In the first group, the defect of the right knee was 
filled with the 8mM polymer and the defect of the left knee was filled with 35.2 mM (n=8). In 
the second group, the right knee defect was filled by 8mM polymer and the left knee filled with 
17.6 mM (n=8). The third group was 17.6 mM polymer in the defect of the right knee and 35.2 
mM in the defect of the left knee (n=8). It is important to note that the PEG-genipin polymer was 
1mm in diameter and the trochlear defect was 1.5 mm in diameter. Upon contact of the hydrogel 
with blood or saline solution, the polymer swelled and fully filled the trochlear defect (Appendix 
Figure 6). This is an important characteristic of this hydrogel that facilitates the surgical 
procedure during the implantation of the polymer in the osteochondral defect. The rats were 
sacrificed after 5 weeks and the distal femurs were harvested and fixed.  
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 Appendix figure 6.  PEG-genipin in osteochondral defect initially. 
C.3 RESULTS AND DISCUSSION 
The dissolution of PEG-genipin scaffolds was inversely related to genipin concentration. 
The lowest concentration (8mM) had a faster dissolution rate with most of the polymer fully 
dissolved (10 out of 16), the remaining knees showed a slight presence of the polymer (6 out of 
10). Intermediate dissolution was observed in the 17.6mM group compared to the other two 
groups.  All of the polymers in the 17.6mM group had partially dissolved. However, none of the 
knees presented total dissolution of the polymer. The highest concentration (35.2mM) offered the 
slowest dissolution at 5 weeks (Appendix Figure 7). 
 136 
 Appendix figure 7.  Gross observation and histology of the knees. 
Gross observation of the knee with 8mM PEG-genipin (a), 17.6mM PEG-genipin (b), and 35.2mM PEG-
genipin (c).  Histology of the knee with 8mM PEG-genipin degraded and almost fully filled (d), 17.6mM PEG-
genipin showing partial dissolution and partial repair (e), and 35.2mM PEG-genipin still present with no 
filling of the defect (f).   
 
The 8mM and 17.6mM PEG-genipin groups demonstrated repair of the osteochondral 
defect in the trochlea. However, the 35.2mM group did not show cartilage repair due to the lack 
of complete dissolution of the scaffold. All 48 knees were compatible with PEG-genipin. No 
inflammatory reaction was seen, no synovitis was observed during the harvesting, and all the 
animals were able to walk properly in the first post-operative day.  
The 8mM group, with a faster dissolution rate, achieved a larger area of the defect filled 
with repair tissue. The 17.6mM group presented either areas filled with the repair tissue or areas 
with the residual polymer. The 35.2mM group presented a small area of dissolved polymer, with 
the dissolution occurring in the outermost part of the polymer.  The 17.6mM provided superior 
extracellular matrix and a larger number of chondrocyte-like cells. These results demonstrate that 
the histological cartilage repair is also genipin concentration-dependent. 
In conclusion, this is the first study to show PEG-genipin as a concentration-dependent 
polymer in vivo, also its viability for intra-articular use for osteochondral defect therapy. Further 
studies are needed in order to enhance cartilage quality utilizing the PEG-genipin hydrogel. 
 137 
Nonetheless, PEG-genipin shows to be a promising polymer to be used in cartilage tissue 
engineering.  An optimal polymer would be an injectable polymer that would gel in situ.  As 
mentioned in Chapter 5, we are working towards this goal. 
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